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NOEL ANDERSON BROWNLEE. Clear Cell Sarcoma of the Kidney and Congenital 
Mesoblastic Nephroma: Cellular and Molecular Characterization of Primary Tumors, Tumor 
Cell Lines~ and Nude Mouse Xenografts Delineate Wilms' Tumor Distinct Histopathogenetic 
Properties. (Under the direction of Dr. DEBRA J. HAZEN-MARTIN) 
Clear cell sarcoma of the kidney (CCSK) and Congenital mesoblastic nephroma 
(CMN) are both pediatric renal tumors that differ from Wilms' tumor based on their 
distinctive histopathologic characteristics and clinical behavior. CCSK is a very malignant 
tumor characterized by a propensity for bone metastases, contrasting the relatively benign 
course characteristic of the majority of Wilms' tumors. CMN, in contrast, is a tumor of the 
newborn usually diagnosed within the first three months of life that is generally cured with 
surgery alone. To investigate further the cellular and molecular relationships of CCSK, 
CMN, and Wilms' tumor, a nude mouse xenograft and cell culture system was established 
for both CCSK and CMN; the immunohistochemical, gene expression, and functional 
analysis of the p53 tumor suppressor in cell cycle control signal transduction was performed; 
and Northern blot analysis of genes relevant to normal nephrogenesis was examined. 
The histologic, ultrastructural, and molecular features of CCSK and CMN nude 
mouse xenografts, some of which have been passaged over several years, retained the 
characteristics of the primary tumors. Similarly, cell cultures derived from either primary 
tumors or mouse xenografts maintained cellular and molecular profiles consistent with 
findings for primary tumors. 
p53 mutation is a marker for poor prognosis in Wilms' tumors. p53 immunoreactivity 
was absent from a large panel of CCSK and CMN primary tumor specimens examined. 
However, immunohistochemical analysis of CCSK and CMN tumor celllines surprisingly 
Xll 
revealed p53 immunoreactivity in both CMN cell lines but in none of the CCSK cells 
examined suggesting that p53 was mutated in the benign CMN tumors. Functional analysis 
ofp53 in the same CCSK and CMN cell culture system using a DNA damaging agent cis-
diamminedicholroplatinum (100 J-lM) demonstrated the presence of functional p53 as 
determined by the upregulation of p21 Waj-IICip-1 mRNA and G 1 cell cycle arrest over an 
eight hour period. 
The histogeneses ofCCSK and CMN is not known. CCSK and CMN primary tumor 
tissue was examined for mRNA expression of the genes WT-l, P AX-2, Pax-8, and tenascin-
C, all genes relevant to normal kidney development. CCSK and CMN were generally 
negative for WT-I, PAX-2, and Pax-8 expression. CMN, but not CCSK tumor specimens, 
were positive for tenascin-C mRNA. To evaluate further the histogenesis of these tumors, 
cultured CCSK and CMN cells were treated with the differentiation agent all-trans retinoic 
acid (1 JlM) over three days. Induction of several genes were noted during this period such 
as PAX-2 and tenascin. The expression of IGF-2, IGF-BP2, and p21 waj-J1cip -1 were also 
modulated by this treatment. There were no light microscopically evident changes in cellular 
morphology in either CCSK or CMN cells. However, transmission and scanning electron 
microscopic analysis of the cells demonstrated closer cellular juxtaposition and flattening. 
These studies indicate that the in vivo and in vitro model system for CCSK and CMN 
will be useful in further investigating the molecular pathological relationships and 
tumorigenic mechanisms in pediatric renal tumors. The apparant absence ofp53 functional 
impairment in CCSK distinguishes this aggressive tumor type from anaplastic Wilms' 
Xll1 
tumors which often bear mutation of p53 and suggests an alternative genetic explantion for 
the poor prognosis ofCCSK. Further, a deeper understanding of the gene expression profile 
of pediatric renal tumors and renal development will be useful in the diagnosis and treatment 
ofCCSK, CMN, and Wilms' tumor. Both the CCSK and CMN xenografts and cell lines also 
have potential utility in understanding the pathobiology of the developing fetal kidney as 
well as other pathologies affecting both children and adults. 
Chapter 1 
Introduction 
I. General Introduction 
Pediatric renal tumors represent the sixth most common childhood malignancy 
following leukemias, brain tumors, neuroblastic tumors, and soft tissue sarcomas 
(Parham,1996). Wilms' tumor, or nephroblastoma, is by far the most common renal tumor 
of childhood, representing 85% of all reported cases (Murphy et al., 1994). Other renal 
tumors with distinct histological and prognostic features also affect the young child. These 
tumors have been classified based on these distinguishing features by the National Wilms' 
Tumor Study (NWTS) group.They include the benign, congenital mesoblastic nephroma, 
(CMN) comprising 5% of all childhood renal tumors, the potentially metastatic clear cell 
sarcoma of the kidney (CCSK) comprising an additional 5% of cases, and the malignant 
rhabdoid tumor of the kidney (RTK) which comprises 2% of all renal tumors of childhood 
and usually metastasizes widely leading to patient death (Murphy et al., 1994).The 
histological differences between the childhood renal tumors are noted in Figure 1. Both 
CMN and CCSK and their relationships with Wilms' tumor will be the subject of the present 
study_ 
Wilms' tumor has been extensively characterized at the morphological, 
immunohistochemical, cytogenetic, and molecular levels (Grundy et al., 1995). In contrast, 
both CMN and CCSK have not been evaluated thoroughly except for a few reports 
describing the light and electron microscopic distinction of these tumors from Wilms' tumor. 
In addition, there are very few studies which have evaluated the molecular pathology of these 
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two neoplasms. Therefore, questions as to the relationship between these two tumors and 
their possible relationship with Wilms' tumor remain unknown. One report has suggested 
that CMN represents the benign counterpart of the more aggressive CCSK (Yun, 1993). This 
theory is based primarily upon the similar stromal histology of these two neoplasms which 
differs from the triphasic histology (Le., consisting of stroma, immature tubuli, and 
blastema) of Wilms' tumor. Although light and electron microscopic studies can provide 
valuable clues to the histogenetic origins of these two tumors, additional cellular and 
molecular based investigations will need to be applied to address this question thoroughly. 
The present study is an effort to address the cellular and molecular biology ofCMN 
and CCSK, detennine if and how these tumor types are related to Wilms' tumor, and 
investigate their histogenetic origins. To address the pathology of CMN and CCSK, the 
following hypotheses are derived from the current literature and preliminary findings: 
1. Both nude mouse xenografts (heterotransplants) and cultured cells derived from 
CMN and CCSK tumor tissue will maintain the characteristics of their respective 
primary tissue and provide models for the future study of these neoplasms. 
2. Both CMN and CCSK cells exhibit different molecular biological aberrations 
which are distinct from those in Wilms' tumor; and, 
3. CMN, CCSK, and Wilms' tumor have distinct histogenetic origins within the 
human developing kidney. 
II. Historical Background 
1. Genetic Etiology of Wilms' Tumor: Initiating Factors 
Wilms' tumorigenesis is thought to occur during the fonnation of the metanephric 
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kidney because the histology of this tumor closely parallels the appearance of the structures 
visible during the course ofnonnal development (Figure 2 ). Specifically, these structures 
include closely opposed blastematous tissue characterized by basophilia and high nuclear to 
cytoplasmic ratio, the formation of immature renal tubular elements, and the presence of cells 
of stromal lineage (e.g., fibroblastic cells, muscle cells, etc.) (Parham, 1996). In addition, 
nephrogenic rests represent foci of undifferentiated renal tissue that are found in 0.01 % of 
all infant autopsies (Murphy et al., 1994). Nephrogenic rests are also found in 0.40% of 
unilateral Wilms' tumor cases and 1.2% of synchronous bilateral Wilms' tumors and are 
thought to be tumor precursor lesions (Park et al., 1993). Although Wilms' tumor is widely 
accepted as an aberrancy of normal renal morphogenesis, the genetic etiology of this 
neoplasm is very complex. 
The genetic basis of Wilms' tumor was initially thought to follow the pattern of 
another embryonal neoplasm, retinoblastoma. Both retinoblastoma and Wilms' tumor may 
occur either sporadically or be familial in nature. This feature led Knudson to describe his 
classical "two-hit hypothesis" years before the actual identification of either the Rb or WT-J 
tumor suppressor genes. His hypothesis stated that those children with bilateral tumors 
inherited one defective allele (i.e., mutated, deleted, etc.) and acquired one additional somatic 
mutation before the development of a tumor. In contrast, mutations in both alleles occurred 
somatically in children with sporadic, unilateral cases of retinoblastoma and nephroblastoma 
(Knudson et al., 1972). 
The genetic etiology of Wilms' tumorigenesis first became evident upon the 
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karyotypic observation that patients with W AGR syndrome (Le., a genetic syndrome 
characterized by Wilms' tumor, aniridia, genitourinary malformations, and mental 
retardation) harbored large germline deletions on one chromosome 11 p 13 allele (Grundy et 
al., 1979). Patients with the W AGR syndrome were later reported to harbor point mutations 
in the other WT-l allele (Baird et al., 1992). Evidence for a putative Wilms' tumor gene 
mounted later with the observation that some sporadic cases of Wilms' tumors, those not 
associated with the W AGR syndrome, demonstrated loss of heterozygosity (LOR) at 
chromosome 11p13 (Fearon et al., 1984; Koufos et al., 1984). The localization of a small 
11 p 13 deletion led to the identification of a gene encoding a (Cys )2-(His)2 zinc finger 
transcription factor at this locus which was designated WT-J (Call et al., 1990). Later work 
showed that alternative RNA splicing at two sites, one of which created a three amino acid 
(KTS) addition between the third and the fourth zinc fingers and the other which deletes exon 
5, produced four discrete WT-J transcripts (Haber et al.,1991). The role(s) of the four 
transcripts remain(s) unclear. 
Additional evidence later came with the observation that patients having Denys-
Drash syndrome, a genetic disease characterized by genitourinary malfonnations and a 
predilection for Wilms' tumor, harbored dominant point mutations that affect the WT -1 zinc 
fingers ( Pelletier et al., 1991). WT-J gennline mutations have also been identified in Denys-
Drash patients and in several cases of bilateral Wilms' tumor (Pelletier et al., 1991; Ruff et 
al., 1991). 
WT-J mutations were later described in nephrogenic rests, foci of primitive renal 
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cells that are found admixed with normal renal tissue in children with or without Wilms' 
tumor and areas thought to represent precursor lesions of Wilms' tumor (Park et a/., 1993). 
In this study, two separate cases of nephrogenic rests harbored a somatic mutation in WT-l 
that was identical to the mutation in the primary Wilms' tumors. WT-J knockout mice studies 
further demonstrated the involvement of WT-J in urogenital development as those mice 
without functional WT-l failed to form a functioning metanephros due to the absence of 
ureteric bud outgrowth. Defects in the mesothelium, heart, and lungs were also reported in 
these same WT-J knockout mice indicating the importance of this gene in other organs, as 
well (Kreidberg, et a/., 1993). Surprisingly, however, constitutional and tumor-specific WT-
1 mutations occur in only 10% of sporadic Wilms' tumor. In addition, many tumors 
contained only one WT-J mutation, with the other allele being apparently normal (Haber et 
aI., 1990). Because most Wilms' tumors overexpress WT-J mRNA and lack any 
demonstrable mutation, other, unexplored mechanisms which inactivate the function ofWT-
1 may exist. 
Insulin-like growth factor II (IGF-2), a fetal mitogen, is reportedly overexpressed 
in Wilms' tumor and several other childhood tumor types (Reeve et al., 1985). Further, the 
use of a monoclonal antibody, aIR3, directed against the cognate receptor of IGF-2, the 
insulin-like growth factor type I receptor (I GF -1 R) inhibited the growth of cultured Wilms' 
tumor cells and the growth ofheterotransplanted Wilms' tumors in nude mice (Gansler et 
al., 1989). In addition, the use of suramin, a polysulfated naphthyl urea compound which is 
thought to interfere with IGF-2 binding with its cognate receptor, IGF-IR, inhibited the 
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growth of Wilms' tumor both in vitro and in tumor xenografted mice (Stein, 1993; Vincent 
et al., 1996a). This information suggests a role for an IGF -2 autocrine growth loop in Wilms' 
tumor" cell growth. 
The in vivo target genes of the WT-l transcription factor during nonnal renal 
organogenesis remain largely unknown. However, putative target genes have been identified 
predominantly through in vitro transactivation experiments. WT -1 appeared to bind 
promoters with guanine-cytosine (GC)-rich DNA sequences such as the early growth 
response (EGR)-l consensus site, and led to transcriptional repression (Rauscher et al., 
1990). One of the presumptive WT-l targets is the IGF-2 gene. The major IGF-2 promoter 
was defined in transient transfection assays as a region spanning from nucleotides -295 to 
+ 135, relative to the transcription start site. WT -1 bound to multiple sites within this region 
and functioned as a potent transcriptional repressor of IGF-2 in vivo (Drummond et al., 
1992). WT-l also modulates the expression of the insulin-like growth factor one receptor 
(IGF-l R), a receptor which mediates the cellular action of the mitogen IGF-2. In a series of 
tumors examined, IGF-1R mRNA levels were inversely correlated with the expression of 
WT-l. Further, in the same study, cotransfection of Chinese hamster ovary cells with rat and 
human IGF-l R gene promoter constructs driving luciferase reporter genes and WT-l 
expression vectors demonstrated that the WT-l gene product represses IGF-1R promoter 
activity (Werner et ai., 1993). This evidence suggests a role for an IGF-2 autocrine growth 
loop as a transforming mechanism in Wilms' tumor cells. 
WT -1 modulation of cell growth is not limited to the insulin-like growth factors and 
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their receptors. In transient transfection assays, WT -1 inhibited transcription of the platelet-
derived growth factor A-chain (PDGF-A) gene, a growth factor overexpressed in many 
tumor types, by binding to a highly GC-rich region of the P DGF-A promoter as assessed by 
gel mobility shift assays (Wang et al., 1992). WT -1 also repressed transfonning-growth factor 
beta one (TGF-fJ) gene expression (Dey et aI., 1994). In other studies, WT -1 repressed the 
Bcl-2, c-myc, and epidermal growth factor receptor promoters suggesting a role for WT -1 in 
the complex control of programmed cell death, or apoptosis (Hewitt et al., 1995; Englert et 
al., 1995). 
The WT -1 gene product is reported to form a physical complex with another tumor 
suppressor protein, p53. This association depends upon the structural integrity of both 
proteins and has implications for both tumor suppressors' function. In the absence of 
functional p53 protein, WTl appeared to attain potent transcriptional activation properties. 
In addition, WTl synergized with p53 by enhancing its trans activating properties in one 
report (Maheswaran et al., 1993). A later study found that the WT -1 gene product stabilized 
the p53 protein and inhibited p53 mediated apoptosis without affecting G 1 cell cycle arrest 
(Maheswaran et al., 1995). More recently, WT-l has been shown to induce the expression 
of the cyclin-dependent kinase inhibitor p21 Waj-lICip-l preceding apoptosis, apparently in a p53-
independent manner suggesting a role for p21 in a WT -1 dependent programmed cell death 
pathway (Englert et al' J 1997). Table 1 A summarizes the action ofWT -Ion its various target 
genes. 
Other potential Wilms' tumor loci have been suggested and include sites located on 
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chromosomes I1p15, 16q, and a familial locus at chromosome 17q (Pritchard-Jones et al., 
1997). The 11 pIS locus, the site of the putative WT -2 gene, was initially identified as a 
region of specific allele loss in Wilms' tumors and later found to contain the genes 
responsible for Beckwith-Wiedemann syndrome (BWS), an autosomal dominant genetic 
disease characterized by fetal overgrowth ( Moulton et al., 1996). Children with BWS have 
a much greater chance of developing malignant tumors including hepatoblastomas and 
nephroblastomas relative to the general population. Approximately 10% of BWS children 
developed a childhood neoplasm in one report (Junien, 1992). 
Several chromosome Ilp15.5 imprinted genes have been implicated in the 
development of both Wilms' tumor and BWS. One of the genes residing at this locus was 
the paternally expressed autocrine growth factor IGF-2 gene, a gene that showed 
pathological biallelic expression in some tissues due to loss of imprinting (Weksberg et al., 
1993). I G F -2 is overexpressed at both the mRN A and protein levels in most cases of Wilms' 
tumor examined (Reeve et al., 1985; Scott et al., 1985), H19 is a maternally expressed, 
untranslated RNA that may serve as a tumor suppressor gene also located at chromosome 
Ilpl5. In one study, the inactivation of H19 correlated with the reciprocal activation of the 
IGF-2 maternal allele in Wilms' tumor and contributed to tumorigenesis either by its cis 
effect on IGF2 expression or via elimination of a trans growth-inhibiting effect of H19 
mRNA, or via both mechanisms (Hao et al., 1993). The actual role of H19 in the modulation 
of IGF2 expression, however, is unclear. 
More recently, attention has focused on another 11 pI5 gene, the cyelin-dependent 
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kinase inhibitor p57KlP2 as a candidate for the WT -2 tumor suppressor. p5 7KlP2 was reported 
as a structurally distinct member of the cyelin-dependent kinase inhibitor family which also 
includesp21wa/-llcip-l and mapped to chromosome Ilp15.5 in the vicinity of reported BWS 
breakpoints (Matsuoka et al., 1995; Hoovers et al.,1995). Analysis of the entire coding 
sequence and intron-exon boundaries of p57K1P2 in 40 unrelated cases ofBWS revealed that 
only two patients (5%) harbored mutations, both of which were frameshift mutations in exon 
two (Lee et al., 1997). Another report which analyzed nine patients with BWS demonstrated 
that 22% of the cases harbored p57K1P2 mutations (Hatada et ai., 1996). Whereas only a few 
cases ofBWS reportedly harbor p57K1P2 mutations, an analysis of twelve primary Wilms' 
tumors revealed no mutations in this cyetin-dependent kinase inhibitor gene (O'Keefe et 
al., 1997). Others have suggested that non-mutation cases ofBWS and Wilms' tumor might 
still be caused by down-regulation of p57KIP2 expression via uni-parental paternal disomy 
(Henry et al., 1991). 
A recent study of one Wilms' tumor pedigree by linkage analysis has suggested 
another potential predisposition gene located at chromosome arm 17q12-q21 (Rahman et 
al., 1996). This study conceded, however, that chromosome 17 can be excluded as the site 
of a predisposing gene in several smaller pedigrees which were examined. 
The initiating genetic factors leading to Wilms' tumor are undoubtedly very 
heterogeneous. WT-J, once thought to be the sale initiating factor for Wilms' tumorigenesis 
is deleted or mutated in only 10% of cases. Likewise, genes located at chromosome 11 p 15 
including IGF2, H19, and p57KlP2 still have unclear roles in the development of Wilms' 
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tumor. The variability and large number of genetic lesions found in Wilms' tumors to date 
testifies to the fact that the tumorigenic factors responsible for the development of this 
childhood neoplasm are very complex and poorly understood. 
2. p53 Signal Transduction: Cell Cycle Control and Apoptosis 
The p53 tumor suppressor gene is located on the short arm of chromosome 17 and 
encodes a 53 kiloDalton (kD) nuclear phosphoprotein that is a negative regulator of cellular 
proliferation (Levine et al., 1991). p53 mutations were relatively common in a large number 
of adult-onset tumor types including breast, lung, and colon carcinomas, but relatively rare 
in childhood malignancies (Nigro et al., 1989). Wild-type p53 was present in extremely small 
quantities in most cell types analyzed due to rapid turnover mediated by the ubiquitin-
dependent degradation pathway (Kastan, 1991). In contrast, tumor cells with a mutant p53 
molecule demonstrated over-expression of p53 protein using either Western blotting or 
immunohistochemistry due to increased stability of the protein (Esrig et al., 1993). 
Therefore, p53 protein overexpression is routinely used as a marker for a mutated p53 gene. 
p53 is a mediator of diverse cellular processes including cell growth arrest, repair 
of DNA damage, and induction of programmed cellular death or apoptosis. p53 protein was 
induced following exposure to DNA damaging chemotherapeutic agents, ionizing radiation, 
and ultraviolet irradiation (Ko et al., 1996). Several studies have suggested that p53 'senses' 
DNA damage by signalling through an upstream initiating factor ATM, or mutated in ataxia 
telangiectasia protein, a protein that is homologous to members of the DNA-protein kinase 
gene family (Hawley et al., 1996). p53 mediates cell cycle arrest and programmed cell death 
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via several downstream effector genes. A substantial number of genes containing p53 
response elements within their promoters have been identified (Table IB). 
The p21 waf-llcip-l is a cyclin-dependent kinase inhibitor which is transactivated by the 
wild-type p53 protein to effect cell cycle arrest. In seminal reports, p21 prevented cell cycle 
progression by binding to cyclin-cyclin dependent kinase complexes and preventing 
phosphory lation 0 f proteins further downstream including the retinoblastoma protein Rb (EI-
Diery et ai., 1993; Xiong et ai., 1993). p21 also blocked the activity of the proliferating cell 
nuclear antigen which is important for S-phase cell cycle entry (Waga et ai., 1994). 
Additional evidence demonstrated that DNA damage created by gamma irradiation induces 
p53-dependent G 1 cell cycle arrest that is mediated, at least in part, by the induction of p21 
mRNA (EI-Diery et ai., 1994). Induction ofp21 is often used as a measure ofpS3 function. 
In a comprehensive report on over 120 cell lines treated with radiation and different 
chemotherapeutic agents,p21 induction at both the mRNA and protein levels were used as 
determinants of the functional integrity of the p53 tumor suppressor gene (O'Connor et ai., 
1997). p21 is also upregulated by p53-independent mechanisms after exposure to 
differentiating agents such as all-trans retinoic acid, butyrate, or dimethylsulfoxide in HL-60 
cells (Steinman et ai., 1994). 
A variety of other p53 mediators have been described. Other genes which contain p53 
response elements include Bax and MDM-2. In a seminal report, Bax was induced in 
response to p53 expression and encoded a pro-apoptotic protein with homology to the 
cellular survival factor Bcl-2 (Miyashita et a/., 1995). The induction of Bax in response to 
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ionizing radiation appeared to correlate with the mutational status of p53 in human cells. 
Cells with wild-type p53 actively induced Bax expression whereas mutant p53 protein failed 
to do so (Zhan et al., 1994). Initiation of the apoptotic cascade appears to depend upon the 
ratios ofBax to Bcl-2 protein. Bax-Bax homodimers favored apoptosis, whereas Bax-Bcl-2 
heterodimers were inhibitors of programmed cell death (Oltvai et al., 1993). Bax is, 
therefore, a link between p53 and the initiation of apoptosis in those cells that are subject to 
stress signals, such as gamma irradiation or challenge with chemotherapeutic agents. 
MDM-2 is a protein which complexes with p53 and inhibits its transcriptional 
activation ability (Oliner et al., 1993). The MDM-2 gene itself was shown to be a 
transcriptional target of p53 which is activated in response to cell damaging signals. The 
latter is suggestive of an auto-regulatory feedback loop which exists between p53 and MDM-
2 (Wu et al., 1993; Burak et al., 1993). In addition, MDM-2 overexpression is known to 
inhibit p53-dependent G 1 cell cycle arrest in response to irradiation. A peak in MDM-2 
protein occurs later than p21 protein offering evidence that MDM -2 can down-regulate p53 
after the cell has repaired DNA damage (Chen et al., 1994). Crystallography experiments 
have recently identified the exact location of the p53-MDM-2 interaction. An alpha-helical 
section of the p53 transactivational domain interacts with a deep hydrophobic cleft of the 
MDM-2 protein leading to the suppression of p53-mediated transactivation (Kussie et 
ai., 1996). More recently, MDM-2 has been demonstrated to promote the rapid degradation 
ofp53 protein counteracting its accumulation following genotoxic stress (Haupt et al., 1997). 
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The role of the MDM-2 proto-oncogene in the development of human tumors is well 
studied. The MDM-2 gene is amplified in approximately 30-40% of all human sarcomas 
analyzed but rarely amplified in a large number of pediatric solid tumors examined (Oliner 
et al., 1992; Waber et ai., 1993). MDM-2 was over-expressed, however, in a number of 
pediatric cases of rhabdomyosarocma (Kaleti et ai., 1996) 
Others p53 target genes include the DNA repair gene GADD45, cyclin-G, the insulin-
like growth factor binding protein-3, an anti-angiogenic molecule, Thrombospondin-l, 
cyclin-D, and several others (Ko et ai., 1996). 
3. p53 and Anaplastic Progression in Wilms' Tumor 
The vast majority of classical Wilms' tumors are cured with the successful 
combination of chemotherapy, radiation therapy, and surgery. A small minority of Wilms' 
tumors (approximately 5.0%) are believed to progress to a more malignant phenotype 
characterized by the development of morphological anaplasia (Parham, 1996). Anaplastic 
cells are defined as those having extremely large nuclei with multipolar mitotic figures, 
hyperchromasia, and great variability in cell size. Anaplasia is associated with a high degree 
of chemotherapeutic resistance, but not necessarily increased tumor aggressiveness. Classical 
Wilms' tumors that have been successfully propagated in nude mice demonstrated no 
evidence of progression to morphological anaplasia after numerous passages. Therefore, 
direct evidence of anaplastic conversion has not been substantiated. One report, however, 
indicated that a metachronous anaplastic tumor developed within the tumor bed of a treated 
classical Wilms' tumor patient, thereby suggesting that classical tumors may progress into 
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its more malignant anaplastic counterpart (Oesterling eta!., 1987). Therefore, this study links 
these tumor histologies together in a continuum of time. More recent molecular biological 
assessment of Wilms' tumors has upheld the putative link between classical and anaplastic 
Wilms' tumors. Figure 3 represents a genetic model of Wilms , tumorigenesis and anaplastic 
progresSIon. 
Several studies have examined the mutational status of the p53 tumor suppressor in 
Wilms' tumor. In one study,p53 was mutated in two out of21 cases examined, or 9.5% of 
all cases. One of the cases harbored morphological features of focal anaplasia (Malkin et al., 
1994). In another more comprehensive study of 140 cases, p53 mutations were documented 
in eight of eleven anaplastic Wilms' tumors; the remaining 129 cases that did not exhibit 
anaplasia did not harbor p53 mutations. The latter suggested that p53 is a marker of 
anaplasia and is a gene, when defective, that is responsible for the poor outcome in patients 
with morphological features of anaplasia (Bardeesy et al., 1994). In another study of three 
anaplastic Wilms' tumors,p53 mutations were documented in two of the three cases. One 
mutation created a truncated protein that was undetectable using immunohistochemical 
methods suggesting that immunochemistry should not be used alone in assessing the 
mutational status ofp53 in these tumors. The other mutation was a point mutation at codon 
273, a "hotspot" mutation, which rendered the protein product more stable and thus 
detectable using immunochemistry. The third case affected an older patient but no mutation 
was detected in this tumor even though immunohistochemical analysis using fixed primary 
tumor tissue suggested the presence of p53 mutations (EI Bahtimi et aI., 1996). 
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Additionally, Lahoti demonstrated a tendency for p53 mutations to occur in the majority of 
a series of invasive and metastatic Wilms' tumors using immunohistochemistry. p53 
immunoreactivity was not, however, limited to either anaplastic or metastatic cases of 
Wilms' tumor. Lahoti suggested that the presence of other p53 binding proteins were 
responsible for the latter immunophenotype in the classical Wilms' tumors (Lahoti et al., 
1996). However, amplification or overexpression of the p53 binding protein MDM-2, which 
can bind to and stabilize the p53 protein creating an immunophenotype similar to a mutated 
fonn of the protein, was not an alternative means for p53 inactivation in a large series of 
Wilms' tumors examined (Bardeesy et al., 1994). 
Anaplastic Wilms' tumors are potentially aggressive tumors that are more resistant 
to the conventional Wilms' tumor chemotherapeutic treatment regimen of vincristine, 
vinblastine, and actinomycin D. A link between p53 mutation and the development of a drug 
resistant phenotype has recently been described. The anaplastic Wilms' tumor cell line W4 
contained a thymine deletion at codon 212 which is responsible for a frame shift leading to 
a TGA stop signal at codon 246. The resulting p53 protein was truncated and non-functional 
(EI Bahtimi et a/., 1996). The W4 anaplastic Wilms' tumor cell line also overexpressed the 
MDR-l gene in a separate study (Re et al., 1997). MDR-J was not ampified in case W4 as 
assessed by Southern blotting, but was overexpressed at the mRNA level. P-glycoprotein 
function in the W 4 cell line was inhibited by the calcium channel blocker verapamil in an in 
vitro daunomycin nuclear fluorescence accumulation assay. Mutation of p53 and 
overexpression of MDR-J in this anaplastic Wilms' tumor was found to be consistent with 
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the clinical outcome of patient W 4, as the patient died of multipile metastatic lesions. 
The MDR-J and p53 genes are functionally linked. In vitro transactivation studies 
containing a reporter gene under the control of the MDR-J promoter indicated that wild-type 
p53 acts as a transcriptional repressor of the MDR-J gene and inactivating mutations ofpS3 
released this gene from repression (Chin et aI., 1992; Nguyen et al., 1994). Evidence from 
studies of the W4 cell line supported these latter findings and suggested that p53 and MDR-1 
are linked to both anaplastic progression and the development of a drug resistant phenotype 
in Wilms' tumors. 
Although p53 is mutated in a high percentage of the anaplastic Wilms' tumor cases, 
other chromosomal linkage studies have suggested the presence of other genes which 
predispose patients to a poor outcome. LOR at chromosome 16q was a non-random 
chromosomal abnormality in a series of Wilms' tumors. Significant loss of areas on 
chromosome 16q were present in nine of 45 informative cases ( Maw et al., 1992). Another 
report indicated that patients with deletions on chromosome 16q had relapse rates 3.3 times 
and mortality rates 12 times that of those patients that do not demonstrate LOR at 
chromosome 16q (Grundy et aI., 1994). The latter study also reported that chromosome 1 p 
LOH in Wilms' tumor was a non-random event and linked to mortality rates three times 
higher than rates for patients without LOH. 
4. Genetic Basis of Kidney Development with Implications for Pediatric Renal Tumor 
Histogenesis 
The development of the kidney begins around embryonic day 19 and progresses 
through the pronephric, mesonephric, and metanephric stages before reaching maturity. The 
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definitive, functioning kidney of the postnatal period and beyond is the metanephros which 
fonns as a result of a mesenchymal-epithelial transition. Around embryonic day 28, the 
metanephric kidney is induced in the sacral intermediate mesoderm (nephrotomes) of the 
trilaminar embryo by the ureteric buds, outgrowths of the distal portions of the Wolffian duct 
(mesonephric ducts). The ureteric buds subsequently penetrate beds of mesenchymal tissue 
termed the metanephric blastema spurring the mesenchyme to condense around the apical 
aspects of the ureteric bud. The ureteric bud and the metanephric blastema exert reciprocal 
inductive effects during this period causing continuation of mesenchymal condensation and 
further bifurcation of the ureteric buds. Later in development, remnants of the ureteric bud 
will constitute the collecting duct system whereas the condensed mesenchymal tissue 
continues to differentiate through several distinct stages including the comma-shaped and 
s-shaped bodies to eventually form the non-vascular elements of the glomerulus, the 
proximal and distal convoluted tubules, and the loops of Henle ( Larsen, 1998). Recent 
studies have begun to elucidate the cellular and molecular mechanisms underlying the 
normal nephrogenesis and will undoubtedly offer new information which may be used to 
interpret renal abnormalities including the development of pediatric renal neoplasia. Figure 
4 presents a diagramatic representation of normal nephrogenesis. 
The WT-J gene, first described in 1990, was localized to an area of chromosome 11 
that was often deleted in Wilms' tumor (Call et a/' J 1990). Besides its mutation or deletion 
in Wilms' tumors, WT-J plays a pivotal role in the development of the mammalian urogenital 
system. In a study of homozygous mutant WT-J mice, the ureteric buds failed to form 
properly leading to degradation of the metanephric mesenchyme and renal agenesis. 
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(Kreidberg et al., 1993). In the mouse fetal kidney, WT-l gene expression was relatively low 
in the uninduced metanephric mesenchyme. Coincident with ureteric bud induction, the 
mesenchyme expressed increased levels of WT-l indicating the importance of this gene in 
this developmental stage (Pritchard-lones et al., 1990; Armstrong et ai., 1992). WT-l 
expression remained high during the formation of the early nephron precursors, but as the 
kidney matured, expression was limited to the glomerular podocytes (Ryan, 1995). 
The Pax genes are other important mediators of the developmental regulation of 
the kidney (Gruss et ai., 1992). The Pax gene family encodes evolutionary conserved 
transcription factors which share a common motif, the paired box, which acts as a DNA-
binding domain. Some of the first experiments which addressed the function of Pax-2 in 
kidney development used gene knockout. Pax-2 knockout mice, specifically Pax2-/w mice, 
failed to develop both kidneys and genitourinary tracts (Torres et aI., 1995). In addition, 
antisense Pax-2 oligonucleotides used in kidney organ culture experiments demonstrated 
mesenchymal condensation failure and absence of epithelial differentiation (Rothenpieler et 
al., 1993). 
Additional studies ofPax-2 function have been addressed in gene expression studies 
of the fetal kidney and Wilms' tumors. In the metanephric mesenchyme, Pax-2 was 
expressed in the early condensates and comma-shaped bodies, but expression declined in the 
S-shaped bodies and was not expressed in mature nephron structures (Dressler et al., 1990). 
U sing in situ hybridization experiments, Pax -2 has also been localized in condensed blastema 
cells of Wilms' tumors (Eccles et ai., 1995). Another report has also indicated that Pax-2 is 
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abundantly expressed in a series of Wilms' tumors examined (Dressler et al., 1992). 
Both WT-l and Pax-2 appear to be involved in a reciprocal modulation pathway. 
Expression of Pax-2 is repressed in the presence of increasing amounts of a WT-J expression 
vector as assessed by chloramphenicol-acetyl transferase reporter gene assays (Ryan et al., 
1995). More recently, another report using deletion mutagenesis experiments indicated that 
Pax-2 positively modulated the expression of WT-J by binding to a sequence between 33 and 
71 base pairs upstream of the WT-J start site (Dehbi, et al., 1996b). 
Additional members of the Pax gene family implicated in early kidney development 
include Pax-8. Somewhat different from Pax-2, Pax-8 was expressed in condensed 
mesenchyme, comma-shaped bodies, S-shaped bodies, and immature tubular structures as 
assessed by in situ hybridization studies. Pax-8 is also expressed in the developing thyroid 
gland and in Wilms' tumors (Poleev et al., 1992). A later study indicated that Pax-8 
expression was localized, in particular, to the condensed blastema cells of Wilms' tumors 
(Eccles et al., 1995). Additionally, in transient transfection and gel-shift assays, Pax-8 was 
demonstrated to transacti vate WT-J by binding to a 38 base pair conserved motif wi thin both 
mouse and human promoters, similar to that which was described for Pax-2 (Dehbi et a/., 
1996a). Members of the myc family of transcription factors are expressed at different stages 
of the kidney in a pattern similar to that of the Pax genes. In particular, N-Myc is highly 
expressed in the condensing mesenchymal tissue during normal nephrogenesis (Mugrauer, 
et al., 1991). 
In addition to the large number of transcription factors involved in kidney 
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morphogenesis, a variety of cellular adhesion molecules and extracellular matrix proteins 
play a role in the proper development of the nephron. One of these extracellular matrix 
proteins with relevance to understanding the histogenesis ofCMN and CCSK is tenascin-C. 
Tenascin-C, also termed cytotactin, is a large hexameric glycoprotein that exhibits site-
restricted expression patterns during the development of several organs and retains 
expression in selected adult organs including the kidney. In addition to the nonnal expression 
pattern of tenascin in the adult, it may be re-expressed in a number of pathologic conditions 
such as sites of inflammation, wound repair, and some tumors (Crossin, 1996). The actual 
function of tenascin is not clearly understood, as tenascin knockout mice have not 
demonstrated apparent pathologies (Saga et al., 1992). 
In the developing kidney, the expression pattern of tenascin is restricted. In one study, 
tenascin was not expressed by uninduced renal mesenchymal tissue, but was detectable in 
the extracellular matrix of mesenchymal cells which surrounded the developing epithelial 
cells. Additionally, tenascin seemed to be restricted only to those cells which gave rise to the 
stroma (Aufderheide et al., 1987). The latter observations are consistent with the importance 
of this molecule in mesenchymal to epithelial transitions which occur during the 
developmental process. As nephrogenesis ceases, tenascin disappeared from the renal cortex 
and was only expressed in the interstitial cells of the deep medulla (Aufderheide et al., 1987). 
In another study, tenascin immunoreactivity was not limited to the renal medullary 
interstitium, but was also found in the glomerulus, presumably secreted by the glomerular 
mesangial cells. In the same report, glomerular tenascin immunoreactivity was found 
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increased in the active phase of glomerulopathies and interstitial nephritides (Koukoulis et 
al., 1991; Gould et al., 1992; Truong et at., 1996). Tenascin immunoreactivity is absent from 
loose mesenchymal cells even though the latter cells are positive for fibronectin and neural 
cell adhesion molecules (Ekblom et al., 1991). The expression of tenascin is distinct from 
the cellular adhesion molecule expression pattern of kidney epithelial cells. These cells are 
negative for tenascin while positive for E-cadherin and laminin-A (known markers of 
epithelial cells in many tissue types). Tenascin, therefore, appears to be a marker for stromal 
cells. The distribution of this protein may be useful in understanding the histogenesis of 
pediatric renal tumors, particularly those which supposedly have stromal origins like CMN 
and CCSK. A summary of the gene expression characteristics of the developing kidney and 
pediatric renal tumors is summarized in Table II. 
Intermediate filament proteins are also useful in understanding the derivation of 
tumors and are employed most frequently by pathologists attempting to define the origin of 
a tumor. For example, desmin and smooth muscle actin proteins are markers for smooth 
muscle cells, while vimentin is a marker for cells of mesenchymal origin. The latter 
intermediate filament proteins are useful in the diagnosis of connective tissue tumors, or 
tf sarcomas. In contrast, cytokeratins are markers for epithelilal cells and are often useful in the 
diagnosis of carcinomas (Junquiera et al., 1992) 
5. All-trans Retinoic Acid (atRA) Induced Differentiation of Tumor Cells 
Retinoic acid is a well-known morphogen (Maden, 1985). As such, it has been used 
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as a chemopreventive agent and a therapeutic agent in some types of leukemia. Retinoic acid 
molecules along with their respective metabolites are analogs of Vitamin A, or retinol, an 
agent with many cellular functions. Of particular importance in the analysis of tumor 
histogenesis are the all-trans (atRA) and 9-cis retinoic acid molecules. The latter agents 
effect their molecular and cellular modulations within the cell by binding to different types 
of nuclear receptors termed retinoic acid receptor (RAR) and the retinoid-X receptor (RXR). 
Both the RAR and RXR are heterocomplexes containing u, f3 and y subunits. Transcription 
of a number of target genes are influenced by binding of either a retinoid-RAR or retinoid-
RXR receptor complexes to retinoid acid response elements (RAREs) within their promoters. 
Two tumor cell types, neuroblastoma and the promyelocytic leukemia cells HL-60, 
are particularly amenable to atRA induced differentiation and have constituted the subject 
of many studies regarding the mechanisms for this process. For example, atRA induced 
growth arrest and neurite formation, structures which resembled axons and dendrites, in 
many neuroblastoma cell lines in conjunction with downregulation of N-myc gene expression 
(Wada et ai., 1992). Decreased expression of the c-myb oncogene also occurred upon atRA 
induced differentiation in neuroblastoma cells (Thiele et ai., 1988). The levels of p53 mRNA 
and protein declined in atRA stimulated LAN-5 human neuroblastoma cells consistent with 
the notion that p53 is no longer needed in non-dividing cells (Davidoff et aI., 1992).Upon 
stimulation with atRA, HL-60 promyelocytic leukemia cells were induced to differentiate 
into cells of the granulocytic lineage (Olsson et ai., 1982). 
More recently, atRA has been investigated in Wilms' tumor for its ability to initiate 
differentiation in a blastemal predominant cell line (Vincent et ai., 1996b). AtRA arrested 
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the proliferation of Wilms' tumor cells as assessed by tritiated thymidine incorporation 
experiments. Arrest of cellular proliferation was associated with downregulation of N-myc. 
However, light microscopic and ultrastructural analysis of these Wilms' tumor cells did not 
exhibit any morphological signs of epithelial differentiation as assessed by the development 
of cell polarity ~ microvilli, or junctional complexes. 
5. Congenital Mesoblastic Nephroma: Molecular Biology and Histogenesis 
CMN is the most common renal neoplasm of infants and was first distinguished from 
the more common Wilms' Tumor by Bolande in 1967 (Bolande et a/., 1967). CMN 
comprised approximately five percent of all pediatric renal tumors in one report with over 
60 percent being diagnosed before three months of age (Murphy et al., 1994). The majority 
of CMNs are benign, with surgery alone proving to be curative. Exceptions to this rule 
include the clinical behavior of cellular (or atypical) CMN which had the ability to recur and 
metastasize following incomplete resection of tumor at surgery (Beckwith et a/., 1986). 
Histologically, the tumor is composed of interlacing fascicles of spindle-shaped fibroblasts 
and myofibroblasts with round nuclei in its classical form (Pettinato et a/., 1989). Atypical 
mesoblastic nephroma, also known as the cellular CMN, is a potentially aggressive variant 
ofCMN with dense cellularity, many mitotic figures, necrosis, and hemorrhage (Joshi et a/., 
1986). 
The histogenetic origin of CMN remains controversial. Nevertheless, it has been 
proposed that this tumor arises from secondary mesenchyme (i.e. mesenchyme no longer 
capable of differentiating into epithelial cells of the nephron, but into cells which form the 
renal interstitium) (Yoon-Jung et a/., 1994). CMNs are generally positive for the 
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intermediate filament proteins desmin and smooth muscle actin, both of which are markers 
for skeletal and smooth muscle differentiation, respectively. CMN is not immunoreactive for 
markers of epithelial cells such as the cytokeratins (Pettinato et al., 1989). One report 
demonstrated immunoreactivity for the Thy-l antigen in both CMN and renal interstitium, 
but not in CCSK or Wilms' Tumor (Hazen-Martin et al., 1993). Some reports suggested that 
CCSK may arise from a progression of the more benign CMN due to similarities in 
histological and ultrastructural appearance (Haas et al., 1984). Others have proposed that 
CMNs and CCSKs are one tumor with the potential to differentiate anywhere along the 
stromal lineage of embryonic development into CMN, atypical (cellular) CMN, or CCSK 
(Yoon-lung et al., 1994). In other words, because all of these tumor types resemble different 
stages of stromal cell differentiation during fetal kidney development, tumorigenic events 
may develop at key points in this developmental process resulting in either the cellular or 
classical CMN, or CCSK. 
Cytogenetic studies of CMN are relatively uncommon. Several studies have shown 
that CMNs are often trisomic or tetrasomic for chromosome 11 (Kaneko et al., 1991). 
Another report using fluorescence in situ hybridization studies of CMN also indicated that 
chromosome 11 trisomy or tetrasomy is a common, non-random finding in a number of 
CMN cases (Schofield et al., 1993). This study also reported an association of extra copies 
of chromosome 11 with the cellular or mixed variant of CMN. In another report, northern 
analysis indicated that two cases of CMN overexpressed IGF-2, a gene localized to 
chromosome 11 p 15 (Tomlison et al., 1992). Overexpression ofIGF -2 is consistent with the 
extra copies of chromosome 11 in these tumors and may represent a tumorigenic mechanism 
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inCMN. 
Molecular evidence for the concept that CMNs derive from the stromal lineage of 
renal stem cells is incomplete. One study reported a lack ofN-myc and WT-J mRNA in two 
cases of CMN, contrasting with the presence of WT-J and N-myc mRN A in Wilms' tumors 
(Tomlison et al., 1992). In addition, WT-J is not expressed in the stromal component of 
triphasic, classical Wilms' tumors (Eccles et al., 1995). The latter observation is consistent 
with the hypothesis that CMN, being stromal in nature, arises from the same renal stem cell 
as the stromal cell present in Wilms' tumors. 
6. Clear Cell Sarcoma of the Kidney: Molecular Biology and Histogenesis 
CCSK is a rare renal tumor affecting young children primarily between the ages of 
one and three years, having a characteristic histologic appearance composed of clear nuclei, 
abundant extracellular matrix production, and a fine interweaving network of blood vessels. 
The latter features distinguish CCSK from the more common Wilms' tumor which is usually 
composed of blastema, immature tubuli, and stromal cells. Clinically, CCSK is separated 
from Wilms' tumors due to a marked propensity to recur after initial treatment and 
metastasize to bone (Murphy et al., 1994). CCSK was first reported as a separate entity by 
Kidd in 1970 when he described the "sarcoma of the kidney"as having a higher incidence of 
bone metastases compared to the relatively benign Wilms' tumor which generally did not 
metastasize (Kidd, 1970). Due to the latter, Kidd emphasized the distinction of CCSK from 
Wilms' tumor in the diagnostic process. Since the initial report in 1970, other reports have 
followed describing this tumor. The term clear cell sarcoma of the kidney as a descriptive 
term for this neoplasm was first suggested in a subsequent paper (Beckwith et al., 1978). In 
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the same year, Marsden and Morgan described this same tumor type and termed the tumor 
bone metastasizing renal tumor of childhood and undifferentiated sarcoma of the kidney, 
respectively (Marsden et al., 1978; Morgan et al., 1978). All of these reports found that this 
tumor was distinguishable from Wilms' tumor based on its distinct histology and predilection 
for the development of metastatic bone lesions. 
The treatment of children with CCSK has been dramatically improved with the 
addition of actinomycin D to the chemotherapeutic and radiation regimen. CCSK patients 
now routinely receive vincristine, actinomycin D, doxorubicin, and cyclophosphamide in 
addition to radiation therapy. Actinomycin D increased the six-year relapse-free survival 
from 25.0% to 63.5% with the overall survival rate now approaching 70%. However, this 
report noted that CCSK had the ability to recur several years after the initial diagnosis, 
therefore necessitating the need for close patient follow-up years after the initial diagnosis. 
This same report has further noted that etoposide and ifosfamide have been used successfully 
in the treatment of CCSK patients (Green et aI., 1994). 
Previous studies of the immunohistochemical and electron microscopic features of 
CCSK have further distinguished this tumor from Wilms' tumors. Ultrastructurally, CCSK 
contained round to oval nuclei with little heterochromatin, small nucleoli, primitive cellular 
junctions, sparse Golgi apparati and endoplasmic recticulum, and a lack of epithelial 
differentiation (Haas et al., 1984). Ishii, however, noted that CCSK had a latent epithelial 
nature evidenced by the fact that CCSK grown in culture produced mucin, had an 
eosinophilic cytoplasm, and contained intracellular canaliculi (Ishii et al., 1989). The latter 
report further noted that some CCSKs, like Wilms' tumors with primitive epithelium, were 
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immunoreactive for cytokeratins 8 and 19, markers of renal tubular epithelium. Other 
immunohistochemical studies indicated that CCSKs were negative for epithelial membrane 
antigen as well as for markers of smooth muscle, endothelial cells, neural tissue, and cells 
of the immune system. CCSK cells were only positive for vimentin consistent with the 
mesenchymal character of this tumor (Looi et ai., 1993). 
The cytogenetic and molecular genetic characteristics of CCSK remain relatively 
scanty. A few case reports do exist, however. Punnett reported the first cytogenetic study of 
CCSK (Punnett et ai., 1989). This study demonstrated a consistent karyotype of 
46,XY,t(10;17)(q22;p13) in all cells examined of an individual patient. The constitutional 
karyotype of peripheral blood lymphocytes from the same patient was normal 46,XY, 
however. Punnett further speculated that p53 may be involved in the tumorigenic events of 
CCSK since this tumor suppressor is located at 17p 13, the region involved in the 
chromosomal breakpoint. Another potential gene interrupted by this translocation was the 
early growth response gene-2 (EGR-2) located at chromosome 10q22. Other reports 
indicated extensive cytogenetic abnormalities in CCSK including a loss of the short arm of 
chromosome 11 (Wang-Wuu et ai., 1990). Another report analyzed four cases ofCCSK and 
found that the majority of cases were normal. However, one case in which the patient 
eventually died was found to have a chromosomal 22 translocation t(2;22)( q21;q 11) (Kaneko 
et al , 1991). Deletion of chromosome 22 in CCSK has also been reported (Douglass et aI., 
1990). Cytogenetic aberrations or LOH at chromosome 22q loci also occur in the RTK, 
another renal tumor of childhood with a poor prognosis (Douglass et al., 1990; Schofield et 
ai., 1996).This association may suggest a common origin for both CCSK and RTK. 
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Molecular biologic characterization ofCCSK is limited. Yun used Northern analysis 
and in situ hybridization and demonstrated that CCSK did not express WT -1 mRNA, a gene 
with known involvement in the early development of the kidney, but was positive for IGF-2 
mRNA (Yun, 1993). Based on these findings along with immunohistochemistry and electron 
microscopy, Yun speculated that CCSK is derived from either loose metanephric 
mesenchyme or from stromal cells at an early stage of differentiation. One study reported that 
the WT-l gene contains no gross abnormalities (i.e. gene rearrangements) in five CCSKs 
examined by Southern blotting (Kikuchi et aI., 1992). More recently, an 
immunohistochemical examination of several cases of CCSK demonstrated strong nuclear 
immunoreactivity using monoclonal antibodies directed against p53, suggesting mutations 
in these tumors types (Cheah et al., 1996). No molecular biological or functional 
confirmation has been performed for these tumors. 
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Figure 1. Hematoxylin and eosin stained sections of pediatric renal tumors. A, cellular 
congenital mesoblastic nephroma; B, clear cell sarcoma of the kidney (m = collagenous 
extracellular matrix material; the arrow indicates the characteristic empty appearing nuclei 
of this tumor); C, classical, triphasic Wilms' tumor (s = stromal tissue, b = blastema, and t 




Figure 2. Histological comparison of fetal kidney tissue and Wilms' tumor. A, fetal kidney 
at approximately 10 weeks of development; B, Classical Triphasic Wilms' tumor. Three 
histologic components are noted in each specimen ( white asterisks = blastema, large arrows 
= immature tubuli, and small arrows = stromal tissue). 
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Figure 3. Model for Wilms' tumorigenesis and progression indicating the proposed sequence 
of WT-l and p53 mutations ( WT == Wilms' tumor; A WT == anaplastic Wilms' tumor). 
Adapted from Re GG et al., Seminars in Diagnostic Pathology 11(2): 126-135, 1994. 
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Figure 4. Normal development of the kidney. A, loose mesenchyme with the beginning of 
mesenchymal condensation; B, condensation around ureteric bud; C, comma shaped stage 
of development; D, S-shaped stage of development; E, early tubulogenesis; F, 
glomerulogenesis with invasion by blood vessels. Adapted from Saxen L, Organogenesis of 
the Kidney, 1987. 
D: 
Fig .. 1._20~A to F . Semi~schematic illustration of- the early development of tb·e 
nephron from condensation to the S ... sbaped body (after Saxen 1984a). 
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Table lA. WT-l Transcriptional Modulation of Target Genes with Proposed Biologic 
Effects 
WT -1 transcriptional transcriptional proposed biological 
target modulation of gene effects of gene 
expression expression regulation 
IGF-2 negative decreased cell 
proliferation 
IGF-1R negative decreased cell 
proliferation 
PDGF-A negative decreased cell 
proliferation 
TGF-fJ negative decreased cell 
growth 
Bcl-2 negative apoptosis 
c-myc negative apoptosis 
p21 waf-I positive apoptosis 
Table lB. p53 Transcriptional Modification of Target Genes with Proposed Biologic 
Effects 
p53 transcriptional target transcriptional biological effects of 
modulation of gene gene expression 
expression modulation 
p21 waf-l positive cell cycle arrest~ 
apoptosis 
Bax positive apoptosis 
MDM-2 positive negative regulator 
ofp53 
GADD-45 positive DNA repair 






Table 2. Summary of Gene Expression Analysis of Developing Kidney Tissue and 
Pediatric Renal Tumors 
Condition WT-l Pax-2 Pax-8 Tenascin -C 
mRNA mRNA mRNA mRNA 
loose 




(induced) renal positive positive positive negative 
mesenchyme 
Wilms' tumors stromal 




CCSK negative some negative some 
positive positive 




Materials and Methods 
I. Tumor Specimens 
Two cases of CCSK and two cases of cellular CMN were obtained from the Surgical 
Pathology division at the Medical University of South Carolina (MUSC). These tumors were 
designated CCSK-2 and CCSK-4. CMN from Muse are referred to as CMN-1 and CMN-2. 
Both CMN-1 and CMN-2 are cellular (atypical) forms of the disease. One case ofCCSK was 
obtained fresh from the Department of Pathology at Wake Forest University School of 
Medicine (WFUSM) and was designated CCSK-BG 1. Two other cases of CCSK were 
provided from Timothy Triche, M.D., Ph.D. of the Children's Hospital Los Angeles and 
were designated CCSK-1 and CCSK-3. 
Snap frozen tissues of two classical and three cellular CMN, five CCSK, and the 
matching adjacent normal kidney for each of the latter tumor types were obtained through 
application to the National Wilms' Tumor Study repository. CCSK cases are designated 
CC209, CC236, CC462, CC50057, and CC50113. CMN cases are designated CMN357, 
CMN458, CMN482, CMN50044, and CMN50524. CMN 357, CMN50524, and CMN50044 
are all cellular forms of the disease designated by the prefix ce-. CMN458 and CMN482 are 
classical forms of the disease designated by the prefix cl-. 
II. Chemicals 
Unless otherwise specified, routine chemicals for use in this study were obtained from either 
Fisher Scientific (Atlanta, Georgia) or Sigma Chemical Company (St. Louis, Missouri). 
Chemical reagents used for electron microscopic studies were purchased from Electron 
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Microscopy Sciences (Fort Washington, Pennsylvania). 
III. Nude Mouse Heterotransplantation 
Primary CCSK and CMN tumors were removed surgically and maintained in either 
saline or Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL,Grand Island, New 
York) supplemented with penicillin-streptomycin and 15% fetal calf serum (Gibco BRL) 
before injection into mice as previously described (Garvin et ai., 1988). Tumor specimens 
were minced finely and injected subcutaneously using a 16-gauge needle into 6-10 week old 
Balb/c nude mice (National Cancer Institute, Bethesda, Maryland). Mice bearing tumors of 
the appropriate size (approximately 8-12 cm3) were sacrificed. Tumor nodules were excised 
aseptically, minced finely, and again injected subcutaneously into additional nude mice. 
Additionally~ excised nude mouse heterotransplant tissue was either snap frozen or used to 
establish cell cultures. Heterotransplant histology was evaluated at each passage to compare 
with the primary tumor specimen. 
IV. Tumor and Heterotransplant Tissue Fixation, Processing, and Hematoxylin and 
Eosin Staining 
Following removal of the tumor or tumor heterotransplant, tissue was minced into 
small pieces (approximately 1-2 cm3) and fixed for 8-10 hours at room temperature in either 
10% neutral buffered formaldehyde (NBF) or Camoy' s solution (60% absolute ethanol, 30% 
chloroform, 10% glacial acetic acid). Following fixation, tissues were stored in either 70% 
(NBF fixed tissue) or 100% (Camoy's fixed tissue) ethanol overnight. On the following day, 
tissues were dehydrated in a graded ethanol series, cleared in xylene, and embedded into 
paraffin wax (Fisher Scientific). 
Five J...lm sections of paraffin embedded tissue were cut using a microtome and placed 
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onto microscope slides (Fisher Scientific). Sections were de-paraffinized for 10 minutes in 
three changes of xylene, and hydrated through a graded alcohol series (100%, 95%, 70%) 
into tap water and stained using hematoxylin and eosin. Briefly, hydrated sections were 
stained in Mayer's hematoxylin for 5 minutes, rinsed in two changes of tap water, dipped in 
0.25% ammonia water until sections were blue, rinsed in tap water again, and stained with 
Johns Hopkins eosin for 15 seconds. Tissue sections were then dehydrated using 
successively two changes of 95% ethanol, two changes of 100% ethanol, and three changes 
of xylene before coverslipping. 
V. Transmission Electron Microscopic Evaluation of Tumor Tissue and Cell Cultures 
Either primary CMN or CCSK tumor tissue was removed and cut into 1 mm3 
fragments and fixed in 2.5% sodium cacodylate buffered glutaraldehyde as the primary 
fixative overnight. On the following day, tissue fragments were rinsed in O.IM cacodylate 
buffer and post-fixed in 2% (w/v) osmium tetroxide in 0.1 M PBS for one hours at room 
temperature. The tissue was then successively dehydrated in a graded ethanol series and 
placed in two changes of propylene oxide for ten minutes each at room temperature before 
infiltration in a series of propylene oxide and Epon 812 (50% propylene oxide/50% epon 
resin for one hour, 25% propylene oxide/75% epon resin for one hour, and 10% propylene 
oxide/95% resin for one hour, all at room temperature). Finally, tissues were embedded into 
pure Epon 812 resin. Resin was allowed to polymerize overnight at 70° C before cutting. 
Epon blocks containing tissue fragments were cut into 100-150 nm sections using an 
ultramicrotome. Sections were placed onto copper grids (Electron Microscopy Sciences). For 
transmission electron microscopic (TEM) analysis, sections were stained with uranyl acetate 
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(15g uranyl acetate in 25 ml of absolute methanol) and lead citrate (30 ml Milli-Q water, 
1.33g lead citrate, 1.76g sodium citrate, and 8.0 ml of 4% sodium hydroxide). TEM 
micrographs at various magnifications were obtained using a JEOL 100S Transmission 
Electron Microscope (JEOL, Peabody, Massachusetts). 
Cell cultures were fixed in situ and treated as described above. Exceptions to the 
above mentioned protocol include substitution of 100% ethanol instead of propylene oxide 
in the infiltration steps. Sections of the cell monolayer were also stained with uranyl acetate 
and lead citrate as above. Electron micrographs were also generated similarly. 
VI. Scanning Electron Microscopic (SEM) Evaluation of Tumor Cell Cultures 
CCSK and CMN tumor cells were plated directly onto Thermanox sterile coverslips 
(Electron Microscopy Sciences) and treated for 24, 48, or 72 hours in the presence of 1.0 
J.lM all-trans retinoic acid. Cells were fixed in 2.5% cacodylate buffered glutaraldehyde for 
1 hour at room temperature, rinsed in O.IM cacodylate buffer, and post-fixed in 2%(w/v) 
osmium tetroxide. Coverslips were then rinsed briefly in distilled water and dehydrated in 
an ethanol series before immersion in hexamethyldisilizane for five minutes at room 
temperature as previously described (Kuhnel et ai., 1989). Hexamethyldisilizane treatment 
was substituted for critical point drying. After air drying at room temperature for 30 minutes, 
coverslips were mounted onto an SEM stub, sputter coated with carbon using a Polaron 
Equipment SEM Coating Unit E5150 (Electron Microscopy Sciences) and visualized using 
a JEOL JSM-541 OL V Scanning Electron Microscope (JEOL). 
VII. Initiation of Tumor Cell Culture 
Primary tumor tissue obtained from the Surgical Pathology division of the MUSC 
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Department of Pathology and Laboratory Medicine and the Department of Pathology at 
Wake Forest University School of Medicine or tissue derived from nude mouse 
heterotransplants was maintained in DMEM supplemented with 15% fetal calf serum until 
time to initiate a cell culture. Tissue was minced within a few hours into small pieces of 
about 2-5 mm and placed into a tissue culture flask coated with Type I collagen (Collagen 
Corporation, Palo Alto, California, USA) and fetal calf serum (Gibco BRL) until tumor 
fragments were attached to this substrate (approximately thirty minutes). Alternatively, 
tumor tissue was minced very finely and subjected to tissue dissociation in type I 
collagenase, 200 units/mg of dry weight and deoxyribonuclease, 400 units/mg of dry weight 
(both from Sigma Chemical Company). Both collagenase and deoxyribonuclease were 
solubilized in Hank's Balanced Salt Solution (HBSS) (Gibco BRL) to a final concentration 
of 1.4 mg/ml of collagenase and 1.0 mg/ml of deoxyribonuclease. Tissue was completely 
covered with this solution and subjected to dissociation in a trypsinization flask for 15 
minutes at 37° C. 
The cell suspension was the filtered through sterile 90J.lm-mesh diameter nylon 
filters. The filter was then rinsed several times in HBSS. The filtrate was subjected to 
centrifugation at 180 g at 4° C for 8 minutes in a Sorvall RT6000D centrifuge (DuPont, 
Newton, Connecticut, USA) in order to obtain a cell pellet. The cell pellet was then 
resuspended in a small volume of media before plating into a Coming tissue culture flask 
(Fisher Scientific). 
Both CMN and CCSK cultures were plated into media with the following 
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characteristics: a 1:1 combination ofDMEM and Ham's F-12 (FI2) medium (both from 
Gibco BRL) prepared using water from a Milli -Q water purification system and subsequently 
filtered through a 0.2}lm sterile filter unit (both from Millipore Corporation, New Bedford, 
Massachusetts, USA). Media was stored at 4° C until use. To prevent fungal or bacterial 
growth, penicillin (final concentration of 100 U/ml), streptomycin ( final concentration of 
100U/ml),and amphotericin B (final concentration of 2 mg/ml) was added to media. 
Penicillin, streptomycin, and amphotericin B were acquired from Gibco. 
At the time of use, the latter combination ofDME and F12 was supplemented with 
insulin (5}lg/ml), transferrin (5}lg/ml), selenium (5J.lg/ml), hydrocortisone (36 ng/ml), and 
triiodothyronine (4pg/ml)(Collaborative Research, Lexington, Massachusetts, USA) as 
previously described (Hazen-Martin et al., 1994) and either 2%, 10%, or 20% fetal calf 
serum (v/v). Cells maintained in T75 Coming tissue culture flasks received 15 ml and T25 
Coming tissue culture flasks received 5 ml of media. Media were replaced every other day 
during the propagation of these cells. Cells were maintained in a 5% C021 95% air incubator. 
Confluent cell cultures in T75 Coming tissue culture flasks were sub-cultured by 
rinsing the cell monolayer with phosphate-buffered saline (PBS), pH 7.3 followed by the 
addition of 3.0 ml of 0.05% trypsin-O.02% EDTA (Gibeo BRL). Cell detachment was 
monitored using an inverted phase contrast microscope. Once cells were released from the 
substrate, trypsin was inactivated in an equal volume of fetal calf serum. Cells were 
centrifuged in a 50.0 ml conical centrifuge tube at 180 g at 4° C for eight minutes. The 
resulting cell pellet was resuspended in 2.0 ml - 5.0 ml of fresh media and plated into 
additional Coming tissue culture flasks. Photomicrographs of cell cultures were recorded 
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using a Zeiss IM35 inverted microscope on 35 mm Kodak Panatomic X-film, ASA 32. 
Cell cultures were routinely frozen for future use in their respective growth media 
with 100/0 dexamethasone (Fisher Scientific). Frozen cell pellets were maintained in a liquid 
nitrogen dewar until thawed for additional studies. 
VIII. Cis-Diamminedichloroplatinum (II) (Cisplatin) DNA Damage Response Assay 
CCSK-2, CCSK-BG 1, CMN-1, CMN-2, and the anaplastic Wilms' tumor cell lines 
W4 and W16 were plated at subconfluence in type I collagen coated T25 Coming tissue 
culture flasks (Fisher Scientific). Cells were subsequently exposed to 1 x 10-4 M cisplatin 
(Platinol™, Bristol-Meyers-Squibb, Princeton, New Jersey, USA) diluted in their respective 
growth media for 2, 4, 6, 8, 10, and 20 hours and maintained at 37°C in a 95% air/5% CO2 
incubator. Control groups did not receive cisplatin. Cells from each time point were collected 
by trypsinization and total cellular RNA and protein was extracted. RNA was 
electrophoresed and transferred to nitrocellulose before probing with cDNA probes specific 
for p21, Bax, p53, and MDM-2 genes. Protein was resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and electro blotted onto nitrocellulose before probing with 
p53 and p21 monoclonal antibodies. Cells were also collected for flow cytometric 
determination of G-l cell cycle arrest and apoptosis. 
IX. All-trans Retinoic Acid Induced Cell Differentiation Assay 
CCSK-2, CCSK-BG1, CMN-l, CMN-2, and SK-N-SH neuroblastoma cells 
(American Type Culture Collection, Rockville, Maryland, USA) were plated at 
subconfluence in type I collagen coated Coming T25 tissue culture flasks (Fisher Scientific). 
Cells were subsequently exposed to 1 x 10-6 M atRA for 24, 48, and 72 hours in the dark at 
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37°C in a 95% air/ 5% CO2 incubator. Control cells were treated similarly excepting atRA 
treatment. At each time point, cells were photographed using a Zeiss inverted phase contrast 
microscope, fixed for both transmission and scanning electron microscopy, and lysed for 
RNA extraction. 
x. Immunocytochemistry Using Peroxidase Labelled Secondary Antibodies 
Cells were plated very sparsely onto Lab-tek chamber slides (Nunc Incorporated, 
Naperville, Illinois, USA) coated with type I collagen and fetal calf serum as previously 
described for Coming tissue culture flasks. Cells were then fixed for 10 minutes at room 
temperature in 3.7% formaldehyde in PB S, pH 7.3 or Camoy' s solution. Subsequently, cells 
were rinsed in 70% alcohol, if fixed in formaldehyde, or 100% alcohol, if fixed in Camoy' s 
solution. Before staining, cells were rinsed several times in PBS, pH 7.3 and permeabilized 
using 0.1 % Triton-X 100. Cells were again rinsed several times in PBS before blocking in 
10% normal horse serum (Vector Laboratories, Burlingame, California, USA) for 30 minutes 
at room temperature. Serum was then drained and cells were incubated in monoclonal 
antibodies against p53 (clone DO-7, 1: 100 dilution), MDM-2 (1 :50 dilution), smooth muscle 
actin (1 :75 dilution), desmin (1 :50 dilution), AE1/AE3 cytokeratin (1 :50 dilution), or 
vimentin ( 1 : 5 0 dilution) (N ovocastra Laboratories Ltd. ,N ewcastle upon Tyne, Great Britain) 
for one hour at room temperature. Cells were then rinsed three times for five minutes each 
in PBS, pH 7.3. and incubated in horse anti-mouse antibody heavy and light chain (1:100 
dilution) (Vector Laboratories). After rinsing three times for five minutes each in PBS, pH 
7.3, cells were treated with avidin-biotin-horseradish peroxidase complex (ABC) provided 
in a Vectastain Elite kit and stained using 3-3 '-diaminobenzidine (Vector Laboratories). Lab-
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teks containing the cells were then dehydrated in a graded ethanol series and xylene and 
coverslipped before microscopic visualization. 
Frozen tumor tissue was embedded in OCT frozen tissue embedding media (Lab-Tek, 
Arlington Heights, Illinois), cut at 5 J.lM in a cryostat, briefly allowed to adhere to a 
microscope slide, and fixed in neutral buffered formaldehyde for one minute at room 
temperature. Tissue sections were then rinsed in PBS, and treated in the same manner as cells 
on Lab-teks. 
Paraffin embedded tissue was cut at 5 mM, deparaffinized in three changes of xylene, 
incubated in PBS, and finally 10% normal horse serum. The remaining protocol is the same 
as that used for cells. 
XI. Immunofluorescence Cytochemistry 
Cells were plated very sparsely onto 35 mm dishes coated with type I collagen and 
fetal calf serum as previously described for Coming tissue culture flasks. Cells were then 
fixed for 10 minutes at room temperature in 3.7% formaldehyde in PBS, pH 7.3 or Camoy's 
solution. Subsequently, cells were rinsed in 700/0 alcohol, if fixed in formaldehyde, and 
100% alcohol, if fixed in Camoy's solution. Before staining, cells were rinsed several times 
in PBS, pH 7.3 and permeabilized using 0.1 % Triton-X 100. Cells were again rinsed several 
times in PBS before blocking in 10% normal horse serum (Vector Laboratories) for 30 
minutes at room temperature. Serum was then drained and cells were incubated in 
monoclonal antibodies against p53 (clone DO-7, 1: 1 00 dilution), smooth muscle actin (1 :75 
dilution), desmin (1 :50 dilution), AEI/AE3 cytokeratin (1 :50 dilution), and vimentin (1 :50 
dilution) (Novocastra) for one hour at room temperature. Cells were then rinsed three times 
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for five minutes each in PBS, pH 7.3. and incubated in rhodamine labelled goat anti-mouse 
antibody(l: 100 dilution)(Jackson ImmunoResearch, West Grove, Pennsylvania) for 30 
minutes at room temperature in the dark. Cells were then briefly rinsed in PBS and mounted 
in 10% glycerol in PBS, pH 7.3 before visualization with a Zeiss epifluorescence 
mIcroscope. 
XII. Flow Cytometry Cell Cycle Analysis 
Approximately 1 x 106 cellsfromculturesofCMN-l, CMN-2, CCSK-2, CCSK-BGl, 
W4, and W16 were plated into collagen and fetal calf serum coated Coming T25 flasks 
(Fisher Scientific) and incubated overnight at 37°C in a 5% C021 95% air incubator. On the 
following day, cells were treated with 100 J.lM cis-diamminedichloroplatinum (Bristol-
Meyers-Squibb for 4, 8, and 20 hours. At each time point, cells were trypsinized in 0.05 % 
trypsin, 0.53M Ethylenediaminetetracetic acid (Gibco).Preparation of cells for flow 
cytometry was performed essentially as previously described (Schandl, et aI., 1997). Briefly, 
cisplatin treated cells were centrifuged after trypsinization at 1000 RPM for 10 minutes at 
4°C, rinsed in PBS, pH 7.3, and centrifuged again at 1000 RPM for 10 minutes at 4°C. Cells 
were then fixed in 1 % formaldehyde for 10 minutes on ice and then rinsed and centrifuged 
as before. Cells were maintained overnight in 80% ethanol at -20°C before staining. On the 
following day, cells were rinsed and centrifuged two times in PBS, pH 7.3. Cells were finally 
stained with propidium iodide staining solution (0.01 J.lg/ml propidium iodide, 0.01 Kunitz 
units RNase I J.lI in PBS, pH 7.3) for 30 minutes in a dark location. 1 x 104 Cells were then 
measured in an EPICS XL-MCL Four-Color Analytical Flow Cytometer (Coulter 
Corporation, Miami, Florida, USA) and analyzed using Phoenix Multicycle Software. 
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XIII. Protein Gel Electrophoresis and Western Blotting 
Cell cultures of CMN, CCSK, and anaplastic Wilms' tumors treated with cis-
diamminedichloroplatinum (Bristol-Meyers-Squibb Pharmaceuticals) were extracted in 
Laemmeli buffer (0.0625 M Tris-CI pH 6.8, 2% sodium dodecyl sulfate, 5% ~­
mercaptoethanol, 10% glycerol, and 0.002% bromophenol blue)( Laemmeli,1970) . Equal 
amounts of protein were then electrophoresed in a 11 % acrylamide (30:0.8 acrylamide: bis-
acrylamide) gel at 90 V in Tris-glycine buffer at room temperature for approximately 21/2 
hours. Subsequently, the polyacrylamide gel was electroblotted overnight at 4°C at 35V in 
protein transfer buffer (20% methanol in tris-glycine buffer) onto a Transblot 0.2Jlm 
nitrocellulose membrane (BioRad,Hercules, California, USA). 
Nitrocellulose membranes were then blocked in 5% Carnation skim milk, 0.05% 
Tween 20 (Blotto) for 15 minutes at room temperature. Blotto was then removed and the 
membrane was probed with a p53 mouse monoclonal antibody, clone DO-7 (1 :5000 dilution) 
(Novocastra) or a 1 :500 dilution of p21 cipl mouse monoclonal antibody (Transduction 
Laboratories, Lexington, Kentucky, USA) in Blotto/0.05% Tween 20 for one hour at room 
temperature. Membranes were then rinsed three times,each for five minutes in PBS/O.05% 
Tween 20 and incubated with al :7500 dilution of horseradish peroxidase conjugated goat 
anti-mouse antibody (Jackson ImmunoResearch) for 30 minutes at room temperature. 
Nitrocellulose membranes were finally rinsed three times, for five minutes each time, and 
developed using enhanced chemiluminescence (ECL reagents) according to manufacturer 
instructions (Amersham, Buckinghamshire, England). Membranes were then exposed to 
Kodak X-OMAT film (Sigma Chemical Company) and developed using a automatic 
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developer (Konica Corporation, Japan). 
XIV. RNA Extraction-Agarose Gel Electrophoresis-Northern Blotting 
RNA was extracted from either snap fozen primary tumor (and/or resulting tumor 
heterotransplants) or cultured cells essentially as previously reported (Chomczynski et al , 
1987). Fresh frozen tissue was pulverized into a fine powder using a mortar and pestle under 
liquid nitrogen. After evaporation of liquid nitrogen, the tissue was lysed in 5.0 ml of 
denaturing solution (4M guanidinium isothiocyanate, 25mM sodium citrate pH 7.0, 0.5% 
sarcosyl, 0.1% B-mercaptoethanol, 0.02% sodium azide). The resulting solution was then 
acidified using 500 J.lI 2M sodium acetate, pH 4.0 and extracted in phenol equilibrated with 
water, 0.1 % hydroxyquinoline, and 0.2% mercaptoethanol, and 49: 1 chloroform: isoamyl 
alcohol solution. After mixing into a homogeneous emulsion, the sample was centrifuged at 
4000 g for thirty minutes at 4°C. The resulting aqueous phase was then removed and 
transferred into another tube and re-extracted in a 1: 1 solution of phenol and chloroform, 
mixed into an emulsion, and centrifuged at 4000 g for 30 minutes at 4°C. The aqueous phase 
was again removed and precipitated in cold absolute ethanol overnight at -20°C. On the 
following day, the latter sample was centrifuged at 3500 g for thirty minutes at 4°C. The 
resulting RNA pellet was then rehydrated in 200 J.lI of water followed by the addition of200 
J.lI of Buffer A (0.4 M sodium chloride, 10mM Tris pH 7.4, 5mM ethylenediaminetetracetic 
acid, 0.1 % sodium dodecyl sulfate) and re-precipitated in cold absolute ethanol for two 
hours at -80°C or overnight at -20°C in an Eppendorftube. The sample was the centrifuged 
at 10000 g for 10 minutes at 4°C. The resulting pellet was then rinsed once in cold 70% 
ethanol and centrifuged again at 10000 g for 5 minutes, dried, rehydrated in water, and 
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concentration measured in a spectrophotometer (Beckman Instruments, Fullerton, California, 
USA). 
Aliquots of 5 f.1g of RNA was loaded into each lane of a 1.2% SeaKem agarose (FMC 
BioProducts, Rockland, Maine, USA)-5 % formaldehyde-IX 3-[N-morpholino] 
propanesulfonic acid gel and was resolved by electrophoresis at 55 V at room temperature. 
To visualize the integrity of the 28S and 18S rRNA species along with smaller RNA 
molecules and determine loading efficiency, the ethidium bromide stained gel was photoed 
for permanent records. The gel was then transferred to a 0.2 mm nitrocellulose membrane 
(BioRad Laboratories) overnight in the presence of lOX SSC using a technique previously 
described (Southern, 1975). After transfer, the nitrocellulose membrane was baked at 88°C 
for 1 Y2 hours in a Napco vacuum oven model 5831 (Precision Scientific, Chicago Illinois) 
and kept in a 4°C cooler until hybridization. 
xv. cDNA Probe Labelling and Nucleic Acid Hybridization 
cDNA fragments ofWT-l, p53, p21, MDM-2, IGF-2, BP-2, MDR-1, Pax-2, Pax-8, 
glyceraldehyde phosphate dehydrogenase (GAPD), Bcl-x, Bax, and Tenascin genes were all 
labelled using a Random Primed DNA Labelling Kit according to manufacturer instructions 
(Boehringer-Mannheim, Indianapolis, Indiana, USA). p53, p21, IGF-2, and GAPD cDNA 
probes were acquired from the American Type Culture Collection. The MDM-2 probe was 
a gift from Dr. Bert Vogelstein (Johns Hopkins University) and the Tenascin cDNA probe 
was provided by Dr. Maria Trojanowska (Department of Rheumatology , Medical University 
of South Carolina). The random priming method of DNA labelling has been previously 
reported (Feinberg et al., 1987) Briefly, 25 ng of DNA was boiled for 3 minutes, quenched 
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on ice, and incubated for one hour at 37°C with 3 f.ll of an equimolar nucleotide mixture (A, 
T, and G), 5 JlI of 10IlCi/1l132P-adCTP (ICN Pharmaceuticals), 2JlI of random hexamers, 
and I f.ll ofKlenow enzyme (total reaction volume = 20 Ill). Labelled DNA was then purified 
using Sephadex (fine) G50 Spin columns per manufacturer procedure (Boehringer-
Mannheim) and ethanol precipitated for one hour at -20°C in the presence of cold DNA 
carrier. DNA was then pelleted by centrifugation at 10000 g for 10 minutes at 4°C. The 
pellet was washed once in 75% ethanol and centrifuged as before. The DNA pellet was then 
rehydrated in 200 III of distilled water and 40 f.ll was counted in a scintillation counter 
(Beckman Instruments). The specific activities of probes used were between 1.5 and 2.0 x 
109 cpm/ Ilg. 
A total of 0.8 x 106 cpm of labelled probe per milliliter of hybridization solution 
(40% formamide, 2.0X SSC, 40mM sodium phosphate, pH 8.0, 200 ug ml sheared salmon 
sperm DNA) was employed in all experiments. Before hybridization, nitrocellulose filters 
were pre-wetted for approximately 30 minutes in hybridization solution. The volume of 
hybridization solution used was determined using 0.08 ml/cm2 of membrane as a reference. 
Nitrocellulose filters were incubated overnight at 52°C in hybridization solution. 
Nitrocellulose membranes were then washed twice (5 minutes each) at room temperature in 
2.0X SSe/O.I % SDS and twice (15 minutes each) at 54°C in O.IX SSC/0.1 % SDS, dried, and 
exposed to X-ray film. Autoradiograms were quantified using Adobe Photoshop version 4.0 
software. 
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XVI. p53 Polymerase Chain Reaction (PCR)- Single-Stranded Conformation 
Polymorphism (SSCP) and DNA Sequencing 
SSCP was performed following methods previously described (Orita et al , 1989; 
Baird et al., 1992). An aliquot of 1.0 Ilg of total cellular RNA was first reverse transcribed 
using an RNA PCR Kit (Perkin-Elmer, Norwalk, Connecticut, USA) and further amplified 
using the following sets of primers specific for exons 2 - 11 of the human p53 gene as 
previously described (El Bahtimi et al., 1996): 
exons 2-4: sense: 5' GACGGTGACACGCTTCCCTGGATT 
antisense: 5' CATCTTGTTGAGGGCAGGGGAGTA; 
exons 5-6: sense: 5' ACAGCCAAGTCTCTGACTTGCACG; 
antisense: 5' GATGGTGGT ACAGTCAGAGCCAAC; 
exons 7-9: sense: 5' GTGGTGCCCTATGAGCCGCCTGAG 
antisense: 5' CTCGAAGCGCTCACGCCCACGGAT; 
exons 10-11: sense: 5' GATGGAGAATATTTCACCCTTCAG; 
antisense: 5' TCAGTGGGGAACAAGAAGTGGAGA. 
The peR mixture contained 10 pmol of each primer set, 2 nmol of each nucleotide (A,G, 
and T), 0.25 U Taq Polymerase, 10 III of buffer specified in the RNA PCR Kit, and 1.0 III 
10 a_32p dCTP ( 10 IlCi/IlI, ICN Pharmaceuticals). Thirty cycles of amplification were 
performed using the following settings on a 9600 Perkin-Elmer Thermocycler: 94°C for 0.5 
minutes, 55°C for 0.5 minutes, and 72°C for 1 minute. A 1.0 III aliquot of the reaction 
mixture was withdrawn and mixed with 100 III of 0.1 % SDS/ 10mM EDTA. Then 2.0 III of 
the latter solution was mixed with 2.0 Jll of SSCP loading buffer (95% formamide, 20 mM 
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EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol). The resulting solution was 
heated to 80DC before loading 1.0 ml of sample into a 6% polyacrylamide gel (90 mM Tris-
borate, pH 8.3, 4mM EDTA, and 10% glycerol).Control samples were not heated at 80DC 
before loading. Samples were electrophoresed for 3 hours at 30 W with the use of a cooling 
fan. After electrophoresis, the gel was dried on filter paper and exposed to X-ray film. 
PCR products demonstrating a mobility shift by SSCP analysis were subjected to 
DNA sequencing on both strands using the appropriate primer set using a Sequitherm DNA 
Cycle Sequencing Kit (Epicentre Technologies, Madison, Wisconsin, USA). The latter is 
based upon the dideoxy chain termination sequencing method previously described (Sanger 
et al., 1977). Either 32 P- or 35S-a-dATP was employed in all sequencing reactions. 
Sequencing reactions were performed in a Perkin-Elmer 9600 thermo cycler using the 
following settings: 95DC for 5 minutes, 95DC for 30 seconds and 70 DC for 1 minute for 30 
cycles and held at 4DC indefinitely. Sequencing reaction products were electrophoresed in a 
6% acrylamide denaturing gel (7M Urea, 4.5 ml of 40% acrylamide, 3.0 mIl OX TBE, 0.248 
ml 10% ammonium persulfate to a final volume of 30.0 ml with distilled water, and 19 JlI 
TEMED) at 1200 V, constant wattage. Gel was then fixed in for 30 minutes in 5% acetic 
acid! 15% methanol, affixed to Whatman filter paper, dried for 30 minutes in a Gel dryer 
(BioRad Laboratories), and exposed to X-ray film. 
Chapter 3 
Morphological and Molecular Characterization of an In vitro and In vivo Model 
for the Study of Clear Cell Sarcoma of the Kidney and Cellular Congenital Mesoblastic 
Nephroma 
I. Introduction 
Clear cell sarcoma of the kidney (CCSK) and congenital mesoblastic nephroma 
(CMN) together comprise 10% of all pediatric renal neoplasms (Murphy et aI., 1994). CCSK 
and CMN differ from the more common Wilms' tumor, or nephroblastoma, in histology and 
clinical behavior. CCSK was first delineated from Wilms' tumor in 1970 as a potentially 
aggressive tumor which has a propensity for metastasizing to bone in some patients (Kidd, 
1970). Thus, some have stressed the diagnostic distinction of this tumor from the relatively 
benign classical, or triphasic Wilms' tumor (Beckwith et al., 1978;Marsden et al., 1978; 
Morgan et al., 1978). Contrasting with the clinicopathological features of CCSK, CMN is 
generally a benign tumor of neonates primarily occurring within the first three months of life 
(Bolande et al., 1967). CMN may be subdivided into the classical and cellular variants. 
Cellular CMN has a tendency to recur and metastasize in some instances ifnot completely 
resected (Joshi et al., 1986). Because both of these tumors demonstrate signs of stromal 
differentiation, some have suggested that CMN, particularly cellular CMN, may represent 
the benign counterpart ofCCSK (Beckwith et al., 1978). The latter suggests a relationship 
similar to that suggested for classical and anaplastic Wilms' tumors (Re et al., 1994; 
Bardeesy et al., 1994). Nevertheless, the histogenetic origins of these two tumor types, their 
molecular genetic relationships with each other, and relationships with Wilms' tumor still 
remain largely unknown. 
The vast majority of the available literature on CMN and CCSK has been limited to 
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morphological studies. CCSK is histologically characterized by the the presence of empty 
appearing nuclei, abundant collagenous extracellular matrix material, and a fine arborizing 
pattern of blood vessels easily recognized using Ulex Europeaus agglutinin staining (Mierau 
et a/., 1989). In some forms, CCSK may be confused with other pediatric renal tumors. For 
example, CCSK may mimic the blastemal predominant Wilms' tumors, congenital 
mesoblastic nephroma, and osteosarcoma. Immunohistochemistry has provided little 
information regarding the origins of CCSK. One report has indicated no reactivity for 
fibronectin, laminin, and epithelial membrane antigen in all tumors examined (Kumar et a/., 
1986). Another study indicated that CCSK was positive for vimentin, a marker for 
mesenchymal cells, but non-immunoreactive for epithelial membrane antigen, von 
Willebrand factor, desmin, S-100 protein, and Mac387 in eight cases examined (Looi et a/., 
1993). In contrast, Wilms' tumor cases in the same report were positive for epithelial 
membrane antigen (in areas of tubular differentiation) and vimentin (in the glomeruloid 
bodies and stromal cells). Ultrastructural studies of CCSK indicate the near absence of 
heterochromatin in tumor cell nuclei, few intracellular organelles, and collagen deposition 
in the extracellular matrix (Haas et a/., 1984). Molecular studies of CCSK are extremely 
limited. One report examined the mRNA expression of the Wilms' tumor suppressor, WT-J, 
and the insulin-like growth factor II (IGF-2) in CCSK. In contrast to Wilms' tumors, CCSK 
did not express WT-J while IGF-2 mRNA levels were high in the same cases in a report of 
two cases (Yun, 1993). 
Two histologically distinct forms of CMN exist: classical and cellular (or atypical). 
Classical CMN is composed of interlacing bundles of spindled mesenchymal cells with 
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moderate cellularity and mitotic activity. Cellular CMN, in contrast, is typically composed 
of larger cells with hyperchromatic nuclei and greater mitotic activity in a denser cellular 
array (Murphy, 1994). The diagnosis of cellular CMN is sometimes problematic due to its 
resemblance to other renal neoplasms including monophasic blastemal Wilms' tumor, 
CCSK, and the R TK. Immunohistochemical studies of both CMN variants have exhibited 
staining for vimentin, desmin, and actin. No reactivity was reported for S-100, cytokeratin, 
epithelial membrane antigen, and Leu7 proteins in these tumor types (Pettinato et al., 1989). 
Ultrastructurally, cellular CMN is characterized by the presence of prominent rough 
endoplasmic recticulum and bands of peripheral cytoplasmic filaments. Ultrastructural 
analysis has not, however, provided a clear definition of the cellular derivation of these 
tumors. 
The biological relationships between CCSK, CMN, and Wilms' tumors are 
enigmatic. The study of CCSK, CMN, and their relationship with Wilms' tumor has been 
particularly hindered by the relative rarity of both of these tumor types. In this study, we 
report the development of both a cell culture and nude mouse xenograft model system for the 
study of CMN and CCSK. Both cultures and xenografts have been surveyed for their light 
and electron microscopic features and gene expression profile at the immunohistochemical 
and mRNA level. We report that nude mouse xenografts and cell cultures maintain cellular 
and molecular characteristics of the corresponding primary tumors in most instances. In some 
CCSK cell cultures, immunocytochemical changes were noted, however, which may have 
implications for tumor histogenesis. 
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II. Results 
1. In vitro Characteristics of CCSK and CMN 
Cell cultures of CMN and CCSK were successfully established from nude mouse 
xenograft tissue and primary tumor tissue, respectively. Tumor tissue was minced into 
fragments and placed into a type I collagen and fetal calf serum coated tissue culture flask 
with approximately 5 milliliters of fetal calf serum-containing growth medium. Cellular 
outgrowth from fragments was noted in cultures within one week. Phase microscopic 
analysis revealed spindle-shaped cells in all cultures examined (Figures 1 &2). Cellular 
CMN-2 often demonstrated round to oval cells in addition to the presence of spindle shaped 
cells (Figure 2B). In addition to the presence of cells with fibroblastic appearance, CCSK cell 
cultures also contained focal areas of close cellular opposition (Figure 1). Table 1 
summarizes this laboratory's experience with development ofCCSK and CMN cell cultures. 
2. Light and Electron Microscopic Analysis of CCSK and CMN Nude Mouse 
Xenografts 
Primary tumor tissue from two cellular CMN and four CCSK were successfully 
heterotransplanted into BALB/c athymic (nude) mice. After tumor volume reaches 
approximately 8-12 cm3, mice were sacrificed before removal of tumor and re-injection into 
subsequent mice. At each passage, tumors were monitored for morphological changes using 
hematoxylin and eosin (H&E) staining and transmission electron microscopic analysis. 
Figure 3 summarizes the light microscopic findings of primary and xenografted CCSK and 
CMN tumors. Figure 3A/A' and Figure 3BIB' correspond to H&E micrographs of cellular 
CMN-l and CMN-2 xenografts, respectively. No CMN primary tumor tissue was available 
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for comparison for either tumor. Figure 3A shows the close cellular opposition of tumor cells 
in an early CMN-l mouse xenograft. Figure 3A' is an H&E micrograph ofCMN-l at nude 
mouse passage 73. Figure 3B is from nude mouse passage 5 and Figure 3B' is from passage 
56. Round to spindle cells with a slightly eosinophilic cytoplasm is a feature of both tumors 
and remains consistent with the histology of cellular CMN tumors. Figure 3C/C' and Figure 
3D/D' represent primary tumor specimens and xenografts of CCSK-2 and CCSK-BGl, 
respectively. Hallmark cells with clear nuclei embedded within eosinophile collagenous 
matrix material were characteristic of CCSK-2 and CCSK-BG 1 primary and xenografted 
tumors. Both CCSK-BG 1 primary tumor and xenograft contained rosette formation as well. 
In all cases, tumor histology between primary tumor and xenograft was maintained. Tumor 
xenograft growth characteristics are summarized in Table 1. 
Representative transmission electron microscopic analysis ofCCSK-2 and cellular 
CMN-l xenograft was also conducted. Ultrastructurally, both CCSK-2 primary tumor and 
xenograft were characterized by cell nuclei nearly devoid of heterochromatin with a small, 
single nucleolus present in most cells. A few, small mitochondria with rough endoplasmic 
recticulum comprise features of the cytoplasm (Figure 4 A&B). Desmosomaljunctions were 
noted in CCSK-2 primary tumor. CCSK-2 xenograft also demonstrated deposition of 
collagenous matrix material between cells, a characteristic finding of primary CCSK tumors 
(Figure 4B). CMN-l early xenograft demonstrated cells with nuclei containing a single 
nucleolus with moderate amounts of heterochromatin. Tumor cell cytoplasm was 
characterized by the presence of few mitochondria and sparse rough endoplasmic recticulum 
(Figure SA). 
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CCSK-2 and cellular CMN-lcell cultures were also examined ultrastructurally. 
CMN-l cells grew in sheets while maintained on a type I collagen growth surface and 
maintained the same bland nuclear and cytoplasmic features of its corresponding xenografted 
tumor. A single desmosomal junction is noted in Figure SB. CCSK-2 cells also grew in 
sheets while maintained on a collagen growth surface. Tumor cells were characterized by 
empty nuclei, prominent rough endoplasmic recticulum, close interdigitation, an the presence 
of intermediate filaments. There was no evidence for collagenous matrix production by 
CCSK-2 cells (Figure 4C). CCSK-BGI cells were characteristically similar. 
3. Immunofluorescent Cytochemical Analysis of Intermediate Filament Proteins in 
CCSK and CMN Cells 
To gain a better understanding of the cellular derivation of both CCSK and CMN, 
tumor cells were evaluated using mouse monoclonal antibodies to desmin, smooth muscle 
actin (SMA), vimentin, and cytokeratin intermediate filaments. Both cell cultures derived 
from CCSK-2 and CCSK-BG 1 did not reveal any desmin or cytokeratin filament staining 
(Figure 6). However, both of these cultures were positive for both vimentin and SMA. 
OVCAR ovarian carcinoma cells were included as a positive control for cytokeratins and 
negative control for muscle specific desmin and actin. 
CMN cells derived from xenograft material (primary tumor tissue was unavailable) 
demonstrated a variable immunochemical profile. CMN-l cells were positive for desmin, 
vimentin, but only focally positive for SMA (Figure 7). In contrast, CMN-2 cells reacted only 
with the vimentin monoclonal antibody. TB208 cells derived from an extrarenal malignant 
rhabdoid tumor were included as a positive control for vimentin protein. OVCAR cells were 
again included as a negative control for muscle cell markers. 
4. WT-l and IGF-2 Northern Analysis 
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To further evaluate the retention of primary tumor features in our in vivo and in vitro 
models, we evaluated their gene expression profile. WT-J and IGF-2 are both genes which 
are highly expressed during fetal kidney development and in Wilms' tumor. Comparative 
mRNA expression analysis of these two genes was performed in CMN-l, CMN-2, CCSK-2, 
and CCSK-BG1 primary tumors, xenografts, and cell cultures alongside primary Wilms' 
tumors and normal kidney cells (Figure 8A). IGF -2 mRNA levels were similar in both CMN-
1 and CMN-2 primary tumors and xenografts. However, IGF-2 message was strongly 
increased in their corresponding cell cultures. In contrast, CCSK-2 and CCSK-BG 1 mRNA 
levels were higher in nude mouse xenografts compared to the corresponding primary tumor. 
Few copies of IGF-2 message was detected in CCSK-BG 1 cultured cells, although 
expression was unchanged in CCSK-2 cells. All primary Wilms' tumors, but not normal 
kidney cell cultures, demonstrated IGF-2 mRNA. 
WT-J mRNA was detected in both cellularCMN cases (Figure SB). In CMN-l, only 
the primary tumor and cultured cells expressed detectable WT-J message. In contrast, WT-l 
was expressed in CMN-2 primary tumor, xenograft, and cultured cells. All four classical 
Wilms' tumors examined contained abundant WT-l transcripts. Normal kidney cell lines 
lacked detectable WT -1 mRNA. 
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III. Discussion 
Study of the cellular and molecular biology of CCSK and CMN has been hindered 
by the lack of a useful experimental model system. In addition to our lack of understanding 
of the inherent genetic defects in CCSK and CMN, the relationship, if any, they share with 
the more common classical Wilms' tumor remains unknown. In the present study, we have 
demonstrated the successful establishment and characterization of cellular CMN and CCSK 
tumor cell cultures and nude mouse xenografts that will be helpful in beginning to 
understand the pathobiology of both tumors. 
The histogenetic origin of both CCSK and CMN has been a debated topic for many 
years. Previous reports have suggested that CCSK has a latent epithelial nature (Ishii et al., 
1989). This hypothesis derived from the observation of mucin production, cytokeratin 
immunoreactivity, and the development of intracellular canaliculi in a series ofxenografted 
and cultured CCSK tumors. That observation contrasts with the histological and 
ultrastructural analysis ofxenografted and cultured CCSK tumors in this study as none of the 
CCSK cases examined exhibited signs of epithelial differentiation as reported by Ishii 
However, our cultured CCSK tumor cells did exhibit focal areas of close cellular opposition 
possibly indicative of their epithelial potential. Nevertheless, immunocytochemical analysis 
ofCCSK cell cultures in this study demonstrated reactivity with both SMA and vimentin but 
not cytokeratin monoclonal antibodies. Vimentin, but not SMA, desmin, or cytokeratin 
protein was detected in primary fixed tissue of CCSK consistent with prior reports (Looi et 
al., 1993). Immunohistochemical data of CCSK cell lines and primary tumor tissue and 
CMN celllines are summarized in Table2. 
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The expression of SMA in our two CCSK cell lines suggests one of two possible 
explanations. Firstly, the collagen matrix or plastic surface of tissue culture flasks may have 
a differentiating effect on CCSK tumor cells. Contamination of CCSK cultures with normal 
smooth muscle cells is unlikely. CCSK-2 and CCSK-BG 1 cell cultures demonstrate cells 
growing in sheets that are relatively undifferentiated, a characteristic feature of tumor cells 
only. In addition, lack of SMA immunoreactivity in CCSK primary tumors is not likely to 
be due to fixation problems as arterial smooth muscle was stained. In any case, SMA 
positivity in CCSK cells has not been reported in immunohistochemical analyses of these 
tumors. Previous studies have reported no reactivity with epithelial membrane antigen, 
fibronectin, laminin, desmin, and neural cell markers (Kumar et al., 1986; Looi et al., 1993). 
CCSK cells were only reactive with vimentin monoclonal antibodies suggesting their 
primitive mesenchymal nature. The hypothesis that CCSK cells are derived from 
pluripotential stem cells has been further supported molecularly with the observation that 
CCSK tumors lack WT -1 expression, a marker for induced renal mesenchymal tissue (Yun, 
1993). In the present study, IGF-2 but not WT-l mRNA transcripts were detected in CCSK .. 
SMA positivity in CCSK cells may suggest that these cells have potential for differentiating 
towards glomerular mesangial cells or arterial smooth muscle cells. Given the abundant 
extracellular matrix deposition of CCSK and glomerular mesangial cells in pathologic 
conditions, future studies evaluating CCSK cells with mesangial cell markers may be useful. 
The histogenesis and pathobiology of cellular, or atypical CMN also remains 
unresolved. The development of nude mouse xenografts that maintained the histologic and 
ultrastructural appearance of their primary tumors made the development of cellular CMN 
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cultures possible. Immunochemical characterization of resulting CMN tumor cell cultures 
revealed desmin, vimentin, and SMA reactivity. These same cells did not react with 
cytokeratin specific antibodies .. The latter findings are consistent with previous reports 
which have documented immunoreactivity for these intermediate filament proteins (Pettinato 
et al., 1989). These data are further suggestive of a smooth muscle derivation of CMN 
tumors. Even though there is some overlap in the immunohistochemical profile ofCCSK and 
CMN, Thy-l immunoreactivity has been reported in CMN, but not CCSK tissue which 
further suggests that CCSK is derived from a more undifferentiated cell type (Hazen-Martin 
et al., 1993). Northern analysis of primary tumors, xeno grafts , and cell cultures 
demonstrated the retention of gene expression characteristics between and among the two 
cellular CMN examined. WT-l and IGF-2 were generally expressed in CMN primary 
tumors, xenografts, and cell cultures. WT -1 expression was absent in two cases of CMN in 
a previous report (Tomlison et al., 1992). The latter report did not identify the histologic 
category ofCMN. The observation ofWT -1 in primary and xenografted cellular CMN in this 
study is a novel finding. These data suggest that cellular CMN are relatively undifferentiated 
tumors that may arise from cellular areas adjacent to the condensing renal mesenchyme. 
Evaluation of the extracellular matrix protein tenascin, a marker ofuninduced mesenchymal 
cells surrounding condensed mesenchyme may be useful in testing this hypothesis(Truong 
et al., 1996). 
Recent experiments in mice have reported expression of the BF -2 winged-helix 
transcription factor in cells of the stromal lineage during fetal kidney development (Hatini 
et al., 1996).In the same study, gene knockout studies ofBF-2 revealed that mesenchyme 
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failed to differentiate into tubular epithelium. In light of these findings, it would be 
interesting to evaluate both CCSK and cellular CMN xenografts for possible expression or 
genetic alteration ofBF -2 as a means offurther comparing these tumors with different stages 
of renal development. In addition, the CCSK xenograft and cell culture model system will 
be useful in evaluating the role of p53 in the genetic etiology of this tumor as previous 
immunohistochemical analyses ofCCSK has suggested the presence of mutations in these 
tumors (Cheah et at., 1996). Finally, additional characterization of both CCSK and CMN 
using the in vivo and in vitro model system reported here will not only provide a better 
understanding of pediatric renal tumors, but also of the normal development of the stromal 
cell lineage. 
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Figure 1. Phase micrographs ofCCSK primary cultures plated on a type I collagen/fetal calf 
serum substrate. A, CCSK-2 cells at 100X; A', CCSK-2 cells at 200X; B, CCSK-BG 1 cells 
at 100X; B', CCSK-BG 1 cells at 200X. Black arrows indicate the stromal, or fibroblastic 
appearance of some of the tumor cells. White arrows indicate a single nucleolus which is 
characteristic of CCSK cells. 
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Figure 2. Phase micrographs of CMN primary cultures plated on a type I collagen! fetal calf 
serum substrate. A, CMN-1 cells at 100X; A', CMN-1 cells at 200X; B, CMN-2 cells at 
100X; B', CMN-2 cells at 200X. The black arrow in A indicates one of the many mitotic 
cells in this photomicrograph. The white arrow in B' indicates the round to elliptical cell 
shape ofCMN-2 cells. 

73 
Figure 3. Hematoxylin and eosin stained sections ofCCSK and cellular CMN primary tumor 
tissue and nude mouse tumor xenografts. A, passage 1 of CMN -1 xenograft; A' , passage 73 
of CMN-l xenograft; B, passage 1 of CMN-2 xenograft; B', passage 50 of CMN-2 
xenograft; C, CCSK-2 primary tumor; C' passage 2 of CCSK-2 xenograft; D, CCSK-BG 1 
primary tumor; D', passage 2 ofCCSK-BG1 xenograft. All micrographs at 250X. 
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Figure 4. A, Transmission electron micrograph of CCSK-2 primary tumor tissue. Arrows 
indicate primitive cellular junctions between two cells. N designates the cell nucleus which 
is usually devoid of heterochromatin in CCSK. RER labels the rough endoplasmic 
recticulum. B, Second passage of a CCSK -2 nude mouse xenograft with a nucleus containing 
a single, prominent nucleolus. The arrow indicates collagenous matrix material which is 
characteristic ultrastructural feature of CCSK. C, Early passage of a CCSK-2 cell culture 
demonstrating the spindle shaped cells growing in layers. The arrow indicates intermediate 
filaments within the cell cytoplasm. RER again marks the location of rough endoplasmic 
recticulum. All micrographs at 12,500X. 
c. 
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Figure 5. A, Transmission electron micrograph of a CMN-I nude mouse xenograft. Cells 
are round to elliptical and contain cell nuclei with heterochromatin and nucleoli (indicated 
by large arrow). The cytoplasm is rather devoid of other organelles. B, Cell culture of a 
CMN-l xenografted tumor demonstrating multilayers of cells. Nuclei of cells generally 





Figure 6. Immunocytochemical analysis ofCCSK primary cultures using mouse monoclonal 
antibodies to desmin, smooth muscle actin (SMA), vimentin, and AEI/AE3 cytokeratin 
intermediate filament proteins. OVCAR ovarian carcinoma cells are included as a positive 
control for AEI/AE3 cytokeratin staining and a negative control for desmin and SMA 
staining. Cells receiving no monoclonal antibody but incubated in secondary goat anti-mouse 
antibody are indicated by omit. 
CCSK-2 CCSK-BG1 OVCAR 
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Figure7. Immunocytochemical analysis ofCMN-1 and CMN-2 cell cultures derived from 
xenograft tissue using mouse monoclonal antibodies against desmin, SMA, and vimentin 
intermediate filament proteins. TB208 cells were derived from an extrarenal malignant 
rhabdoid tumor, a positive control for vimentin. OVCAR ovarian carcinoma cells are 
negative controls for desmin and SMA. Cells that received no monoclonal antibody but were 
incubated in secondary goat anti-mouse antibody are designated by omit. 
CMN-1 CMN-2 TB208 OVCAR 
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Figure 8. Northern analysis of primary tumor (P), xenograft (X), and cell culture (e) mRNA 
using cDNA probes specific for: A, the WT-l tumor suppressor and B, the fetal mitogen 
IGF -2. WT -1 expression is absent in most cases. Primary Wilms' tumors (W) were included 
as a positive control for WT-l mRNA. Normal renal interstitial (RMIe), glomerular 
mesangial (HMC), and kidney epithelial (PTe) cells were included as negative controls for 
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Table 1. Summary of CCSK and CMN Xenograft anf Cell Culture Characteristics 
Tumor xenograft current xenograft cell cultures culture subculture 
Specimen turnover passage num ber derived growth frquency 
time medium 
CCSK-1 1 month >90 no N/A N/A 
CCSK-2 2.5 months 5 yes (primary 2%FCS in 2 weeks 
tumor and DMEIF12 
xenograft) 
CCSK-3 2.5 months 12 yes (xenograft 2% FCS in 1 month 
only) DMEIF12 
CCSK-4 failure N/A N/A N/A N/A 
CCSK-BG1 2.5 months 2 yes (primary 20% FCS in 2 weeks 
tumor and DMEIF12 
xenograft) 
CMN-1 1 month > 80 yes (xenograft 2% FCS in 1 week 
only) DMEIF12 
CMN-2 1 month >60 yes (xenograft 20/0 FCS in 2 weeks 
only) DMEIF12 
Chapter 4 
Characterization of the p53 Signal Transduction Pathway in Clear Cell Sarcoma 
of the Kidney, Congenital Mesoblastic Nephroma, and Anaplastic Wilms' Tumor 
I. Introduction 
Clear cell sarcoma of the kidney (CCSK) is a potentially aggressive renal neoplasm 
of childhood with a proclivity for the development of bony metastases (Parham et al., 1996). 
CCSK, first delineated from the more common Wilms' tumor in the 1970s (Kidd, 1970). This 
tumor is distinguished from other renal tumors of childhood based on its more aggressive 
clinical behavior and distinct histological characteristics including clear, empty appearing 
nuclei and abundant extracellular matrix production (Kidd, 1970; Beckwith et al., 1978). 
CCSK is classified by the National Wilms' Tumor Study in the same category as other 
childhood renal tumors with poor prognosis including anaplastic Wilms' tumors and the 
malignant rhabdoid tumor (Murphy et al., 1994). In contrast to CCSK, the congenital 
mesoblastic nephroma (CMN) is a benign tumor which primarily affects neonates, usually 
being diagnosed within the first three months of life. First described in the late 1960s, CMN 
is a relatively benign tumor of the kidney which is usually cured with surgical resection 
(Bolande et al., 1967; Wigger, 1969). CMNs may be further classified into the classical and 
cellular (atypical) CMN based on histopathology and clinical behavior (Joshi et al., 1986). 
In contrast to the wealth of molecular genetic knowledge concerning Wilms' tumorigenesis, 
few reports exist describing the molecular basis for disease in CCSK and CMN. Some have 
speculated, however, that CMN may represent the benign counterpart to the more malignant 
CCSK (Beckwith, 1974). 
Anaplastic Wilms' tumor (a WT) is another renal tumor affecting young children 
which bears a poor prognosis. a WT is thought to develop as a result of a progression event 
from the more common classical, or triphasic Wilms' tumor (Re et al., 1994; Bardeesy, et 
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aI., 1994). Several studies have implicated mutations in the p53 tumor suppressor gene in the 
development of anaplasia. In a comprehensive study of 140 Wilms' tumors, p53 mutations 
were documented in 73% of tumors with anaplastic histology. The remaining 129 tumors 
which did not exhibit morphological anaplasia lacked p53 mutations (Bardeesy et al., 1994). 
Other reports have indicated that p53 mutations were associated with anaplastic tumors 
which were invasive and metastatic (Lahoti et al., 1996). Additionally, EI-Bahtimi reported 
p53 mutations in 67% of anaplastic tumors and no mutations in a series of classical tumors 
examined (EI Bahtimi et al., 1996). Others have associated the presence of p53 mutations 
in anaplastic Wilms' tumors with the development of the multi drug resistance phenotype. 
One Wilms' tumor cell line, W4, bearing a homozygous p53 mutation overexpressed the 
multi drug resistance (MDR-l) gene which codes for the P-glycoprotein, or multi drug 
resistance transporter, an integral membrane ATP-dependent pump which prevents 
accumulation of chemotherapeutic agents in the cytoplasm (Re et al., 1997). Therefore, 
circumstantial evidence appears to support a role for p5 3 in the development of anaplasia and 
resistance mechanisms in these tumors. Because CCSK is a potentially aggressive renal 
tumor of childhood like aWT, it was hypothesized that abnormalities involving p53 are 
implicated in CCSK umorigenesis. One report has indicated possible p53 mutation in a 
series ofCCSK based on immunohistochemical p53 reactivity in a series of formalin fixed 
paraffin embedded tumor specimens (Cheah et al., 1996). Neither cellular nor classical 
CMNs have been evaluated for p53 immunoreactivity to date. 
The p53 tumor suppressor is located on chromosome 17 and encodes a nuclear 
phosphoprotein which acts via several signal transduction pathways to elicit either G 1 or 
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G2/M cell cycle arrest, or apoptosis (Levine et al., 1991). Normally, p53 is induced following 
exposure to ionizing or ultraviolet irradiation and chemotherapeutic agents (Ko et al., 1996). 
The p53 protein mediates cell growth control by transcriptional modulation of a number of 
effector genes which contain a consensus p53 binding site within their respective promoters. 
The p21 wafllcipl (p21) protein is a cyclin-dependent kinase inhibitor which is transactivated 
by wild-type p53 protein to elicit cell cycle arrest (EI-Diery et al., 1994). This kinase 
inhibitor is induced in cells that have sustained DNA damage by irradiation or exposure to 
chemical agents (EI-Diery, et al., 1993). The p21 protein mediates cell cycle arrest by 
binding to and inhibiting the kinase function of eye lin- cyclin dependent kinase complexes 
and preventing phosphorylation of downstream proteins including the transcription factor Rb, 
an event which frees the E2F transcription factor to positively regulate the transcription of 
cyclins. In addition, p21 binds and inhibits the function of the proliferating cell nuclear 
antigen, a protein controlling S-phase entry (Waga et al., 1994). In other reports, p53 
mediates apoptosis by trans activating the pro-apoptotic gene Bax, a gene encoding a protein 
with homology to Bcl-2 (Miyashita et al., 1995). Furthermore, studies have indicated that 
wild-type, but not mutant, p53 molecules induced Bax expression (Zhan et al., 1994). 
Transcriptional targets of p53 also include MDM-2, a gene which is amplified in some 
sarcomas and is involved in negative regulation of p53 (Oliner et al., 1992; Momand et al., 
1992). The induction of MDM-2 by p53 after repair of DNA damage establishes an auto-
regulatory feedback loop (Wu et al., 1993; Burak et al., 1993). The status of these signal 
transduction pathways controlled by p53 has not been investigated in CMN and CCSK 
largely because cell lines derived from these tumors have not been established. This 
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laboratory, however, has been successful in establishing both CMN and CCSK cell lines 
which will be useful in evaluating the genetic mechanism(s) of disease in these two renal 
tumors of childhood. 
To evaluate the gene status and functional integrity of the p53 signal transduction 
pathway in CCSK and CMN, we have evaluated both primary tumors and cell lines for 
immunohistochemical expression of p53 protein in conjunction with gene structure analysis. 
Furthermore, using cell lines, we have evaluated the functional state of p53 by the 
transactivation ofp21, Bax, and MDM-2 in response to DNA damage following exposure to 
cis-diamminedichloroplatinum (cisplatin), a chemotherapeutic agent known to generate single 
and double strand breaks in DNA. Using Northern analysis, we also examined these tumors 
for evidence of MDM-2 or MDR-l overexpression. We report that p53 protein is detectable 
immunohistochemically in our CMN, but not our CCSK cell lines. However, 
immunohistochemical analysis ofprimary CCSK and CMN tumors failed to demonstrate p53 
protein immunoreactivity. Functional analysis of p53 in both CCSK and CMN cisplatin 
exposed cell lines demonstrated transactivation ofp53 target genes including p21, Bax, and 
MDM-2. In addition, MDM-2 was not overexpressed in any of the CCSK or CMN primary 
tumors demonstrating that amplification or overexpression of this gene is not relevant to the 
pathogenesis of these two stromal renal tumors of childhood. 
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II. Results 
1. p53 Immunochemistry, SSCP, and DNA Sequencing Analysis 
Immunochemical staining of p53 is routinely used to screen for mutations of p53 
(Esrig et at., 1993). Immunofluorescent staining ofp53 was evaluated in two CMN and two 
CCSK cell lines developed in this laboratory using the mouse monoclonal antibody DO-7, an 
antibody that recognizes both wild-type and mutant forms of the protein. Immunoreactive p53 
was detected in both CMN cultures, but in neither of the CCSK cultures examined (Figure 1). 
OVCAR ovarian carcinoma cells and the anaplastic Wilms' tumor celllineW16 harboring a 
previously described p53 hotspot mutation were included as positive controls for p53 protein. 
W4 anaplastic Wilms' tumor cells harboring a homozygous p53 mutation were not 
immunoreactive with the DO-7 mouse monoclonal antibody. 
To reconcile nuclear p53 staining in the CMN cell lines and its absence from CCSK 
cells, a panel of CCSK and CMN primary tissues were examined using immunoperoxidase 
methodology. Five fresh frozen tumors and four paraffin embedded tumors of CCSK 
examined did not reveal nuclear p53 protein regardless of tumor stage (TableIA). Further, 
examination of 3 cellular and 2 classical CMN failed to demonstrate nuclear reactivity. 
Paraffin embedded tissue matching the immunoreactive cell lines also lacked demonstrable 
p53 protein expression. An esophageal squamous cell carcinoma containing a previously 
documented p53 mutation demonstrated nuclear activity and was used as a positive control. 
CMN-l and CMN-2 cells, both demonstrating nuclear immunoreactivity for p53 protein, and 
CCSK-2 cells were subjected to SSCP analysis to screen and direct DNA sequencing to 
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confirm the identity ofp53 mutations (Table IB). No mutations were detected using primers 
specific for exons 2-11 of the p53 gene in either of the two CMN cell lines. 
2. mRNA Induction of Cisplatin Treated Tumor Cells 
Both p53 immunochemistry and DNA sequencing fail to evaluate the function of the 
p53 protein. In order to assess whether or not the function of this tumor suppressor was 
impaired in the p53 immunoreactive CMN cell lines, we treated our cell lines with a DNA 
damaging agent using an approach similar to previous experiments (0' Connor e tal., 1997). 
CCSK cells which were not reactive with the p53 protein were included as a 
comparison.CMN-l, CMN-2,.CCSK-2, CCSK-BG1, anaplastic W4, and anaplastic W16 cell 
cultures were treated for four and eight hours with 100 J..lM cisplatin and evaluated for their 
induction of p21 and p53 using Northern analysis (Figure 2). Hybridization with a GAPD 
cDNA probe was included as a control (Figure 2C). Both CMN and CCSK cell cultures 
demonstrated induction ofp21 mRNA, compared to an untreated control (0 hours), over an 
eight hour period (Figure 2A). Anaplastic W4 cells which are homozygously mutant for p53 
failed to show p21 induction. Anaplastic W16 cells containing a point mutation at codon 273 
in the p53 gene revealed a slight p21 induction over the same time period. In contrast to p21 
induction, p53 mRNA levels remained unchanged in cisplatin treated CMN cells and declined 
in both CCSK cell cultures (Figure 2B). p53 mRNA was undetectable in the W4 cell line and 
declined over eight hours in W16 cells treated with cisplatin. 
CMN-l, CCSK-2, and CCSK-BGI cells were further analyzed for the ability ofp53 
to transactivate other target genes including Bax and MDM-2 over 20 hours exposure to 
cisplatin using northern blot analysis (Figure 3 A&B). Hybridization of filters with p21 and 
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p53 eDNA probes revealed, again, the upregulation ofp21 mRNA in all cell lines examined. 
Whereas p21 induction begins at 2 hours in CMN -1 cells, increased levels of p21 mRNA are 
not seen in CCSK-2 and CCSK-BG1 cells until 4 and 6 hours. p53 mRNA levels remain 
stable early and decline late in all cell cultures examined (Figure 3 A&B). Induction of the 1.0 
kb Bax-a mRNA was seen in CMN-1 and CCSK-2 cells. In contrast, Bax-a mRNA levels 
declined in CCSK-BG 1 cells. Additionally, Bcl-X mRNA expression diminished with time 
after cisplatin exposure (Figure 3C). MDM-2 expression was variable in both CCSK cell 
cultures. CMN-1 cells revealed an initial increase ofMDM-2 mRNA at 2 hours exposure 
before subsequently declining. 
Quantification of p21, p53, MDM-2, Bax, and Bcl-X mRNA was performed to 
establish the extent of gene expression modulation in CMN -1, CCSK -2, and CCSK -BG 1 cells 
after exposure to cisplatin (Figures 4-7). In both CMN-l and CCSK-2 cells, p21 mRNA levels 
increased three times after exposure to cisplatin. The strongest induction of p21 occured at 
4 hours in CMN-l cells and at 10 hours in CCSK-2 cells (Figure 4). Expression ofp21 in 
CCSK-BG 1 cells increased between four and six hours even though the extent of induction 
was less than that demonstrated by CMN-l and CCSK-2 cells. In all cell lines, p53 mRNA 
levels remained relatively stable or declined (Figure 5). Uniquely, CCSK -2 cells demonstrated 
fluctuations in p53 gene expression over twenty hours of exposure to cisplatin even though 
its expression did not exceed that of the control, or untreated cell culture. MDM-2 expression 
was induced between two and four hours in CMN-l cells and between four and six hours in 
CCSK-2 cells (Figure 6). MDM-2 expression declined in CCSK-BG 1 cells between two and 
four hours before recovering at six hours. Measurement ofBax and Bcl-x was performed to 
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determine the integrity of the apoptotic signalling pathway in CMN and CCSK cells. In CMN-
1 cells, Bax mRNA levels increased 1.5 times between two and eight hours after exposure to 
cisplatin (Figure 7). Bax gene expression also increased by 2.5 times in CCSK-2 cells after 
10 hours of cis plat in treatment. In both CMN-l and CCSK-2 cells, expression of the anti-
apoptotic gene Bcl-X decreased over twenty hours of treatment. 
3. Stabilization of p53 Protein in Cisplatin Treated Cells 
In the presence of a DNA damaging agent or irradiation, p53 protein is readily 
stabilized in cells (Kastan et al., 1991). Due to p53-mediated trans-activation of p21, 
increased amounts ofp21 protein also provide evidence for a functioning p53 molecule. To 
evaluate p53 stabilization and p21 accumulation after exposure to cisplatin, protein extracts 
were prepared from cisplatin treated CMN -1 and CCSK -BG 1 cells over a 20 hour period and 
analyzed by western blot (Figure 8). CMN-l and CCSK-BGI blots probed with p53 
monoclonal antibody (clone DO-7) demonstrated increased p53 protein expression (Figure 
8A). W4 cells and W16 cells were included as a negative and positive control, respectively, 
for p53 protein expression (Figure 8B). Increased p21 expression was noted in both CMN-l 
and CCSK -BG 1 cells. p21 protein levels peaked between 6 an 10 hours in CMN-l cells and 
between 2 and 6 hours in CCSK-BGI cells (Figure 8C). 
Comparative quantification ofp53 mRNA and protein levels in CMN-l and CCSK-
BO 1 cells after exposure to cisplatin was also performed (Figure 9). In CMN-l cells, p53 
protein levels increased over four times over a twenty hour period. In CCSK-BG 1 cells, p53 
protein expression increased over eight times as compared to the control (untreated) sample. 
Levels ofp53 mRNA steadily declined in both CMN-l and CCSK-BGI cells over twenty 
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hours. 
4. Flow Cytometric Evaluation of G 1 Cell Cycle Arrest 
Flow cytometric cell cycle analysis using propidium iodide staining was included as 
a final test to evaluate the ability of the p53 immunoreactive cell lines to arrest in G 1 or G2 
phase of the cell cycle following DNA damage by cisplatin. CMN-l and CMN-2 cell lines 
were evaluated for their ability to arrest in G 1 phase of the cell cycle after treatment with 
cisplatin. CMN cells were compared to the p53 null anaplastic Wilms' tumor cell line W4. 
Both CMN cultures exposed to cisplatin demonstrated G 1 arrest after four hours of cisplatin 
exposure (Figures 10-12 and Table II). CMN-2 cells demonstrated a marked increase in the 
percentage of cells at G 1 after 2 hours of exposure to cisplatin. CMN -1 cells, in contrast, 
appeared to arrest more slowly. In contrast, the p53 null W4 cell line exhibited little to no 
increase of cells in G 1 phase over the same time period. 
5. Steady State mRNA Expression ofp53, p21, MDM-2, and MDR-l in CCSK and CMN 
Primary Tumors. 
The use of northern analysis was employed in the evaluation of the steady-state levels 
of elements of the p53 cell signalling pathway. The presence ofp53 mRNA was used to rule 
out deletion of this gene while steady-state p21levels suggests the normal functioning of the 
p53 protein as well. Evaluation for MDR-J expression was included as a comparison to 
Wilms' tumors as some anaplastic tumors overexpress this protein (Re et al., 1997).Total 
cellular RNA was extracted from CCSK primary tumors and analyzed using northern analysis 
(Figure 13). RNA was probed withp53, p21, MDM-2, MDR-1, and GAPD cDNA fragments 
to evaluate the steady-state expression of these genes in CCSK primary tumor specimens. KB-
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VI, an epidermoid carcinoma cell line, was included as a positive control for amplification 
of the MDR-l gene. SJSA-l pluripotential sarcoma cells were included as a control for 
MDM-2 amplification. p53 and p21 mRNA levels were detected in all CCSK tumor 
specimens examined. There was no evidence for gross gene rearrangement of p53 or MDM-2 
overexpression in any CCSK case examined. There was also no evidence for MDR-l 
amplification or overexpression in CCSK primary tumors. Hybridization with a GAPD cDNA 
fragment was included as a marker for constitutive gene expression. 
Northern analysis ofCMN primary tumors was also conducted using probes specific 
for p53, p21, MDM-2, and GAPD (Figure 14). All primary tumors expressed detectable levels 
of both p53 and p21 mRNA with no evidence of a gross p53 gene rearrangement or deletion. 
MDM-2 expression was detected at low levels in 2 classical CMN cases. There were no 
differences in gene expression between classical and cellular variants ofCMN. 
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III. Discussion 
Mutations of the p53 tumor suppressor gene appears to constitute at least one 
mechanism of tumor progression in the potentially aggressive and drug-resistant anaplastic 
Wilms' tumor. In a study of 11 Wilms' tumors with anaplastic features, p53 mutations were 
documented in 73% of cases (Bardeesy et al., 1994).Other reports have indicated p53 
mutations in 66% of anaplastic tumors (EI-Bahtimi et al., 1996). Others have correlated p53 
protein immunoreactivity with poor outcome in Wilms' tumor (Lahoti et al., 1996). A p53 
mutation was also linked to overexpression of the MDR-J gene in an anaplastic Wilms' tumor 
that led to patient death (Re et al., 1997). Because of the association ofp53 mutations with 
pediatric renal tumors bearing poor prognosis, p53 protein expression was examined by 
immunohistochemistry in a series of CCSK, another potentially aggressive childhood renal 
tumor with a propensity for bone metastases (Cheah et al., 1996). This report indicated that 
nuclear p53 protein was detectable in all eight cases examined leading to speculation that 
there may be a common genetic mechanism leading to resistance and poor outcome in 
pediatric renal tumors. This hypothesis was further bolstered a report of a translocation 
(10;17) breakpoint involving chromosomel7pl3, the site of the p53 gene locus (Punnett et 
al., 1989). 
To begin to test such a hypothesis, we examined CCSK and CMN cell cultures, 
primary tumors for p53 protein and mRNA expression using immunochemistry and northern 
analysis, respectively. p53 nuclear accumulation is an established marker for p53 mutations 
so cells which demonstrate immunoreactivity may harbor p53 mutations (Esrig et al., 
1993).Both CMN cell cultures and CCSK cell lines were initially evaluated for p53 
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expression. Surprisingly, p53 nuclear reactivity was exhibited by cells derived from the 
benign CMN and not in CCSK tumor cells. Subsequent SSCP and DNA sequencing failed 
to demonstrate the presence of a p53 mutation in these immunoreactive cells. To eliminate 
the possibility that p53 nuclear reactivity in CMN cells was not a characteristic only found in 
cell cultures, a series of CCSK and CMN frozen and paraffin embedded tumors were 
examined. This experiment did not show p53 nuclear reactivity in any of the tumor sections 
examined. In the absence of p53 mutations, overexpression of the p53 binding protein and 
oncoprotein MDM-2 constitutes an alternative means of p53 inactivation (Mom and et al., 
1992). In addition, MDM-2 is amplified in many bone and soft tissue sarcomas leading to the 
hypothesis that MDM-2 amplification or overexpression is a plausible occurrence in the 
"sarcomatous" renal tumors of childhood. Furthermore, MDM-2 overexpression stabilized 
p53 protein in rhabdomyosarcoma cell lines (Keleti et al., 1996). This led to the hypothesis 
that MDM-2 may provide an explanation for the p53 nuclear reactivity in our CMN cultures. 
N orthem analysis of both CMN and CCSK primary tumor tissue did not reveal any evidence 
for MDM-2 amplification or overexpression, dismissing the role of this gene in CMN and 
CCSK tumorigenesis. The lack ofMDM-2 overexpression in these tumors is consistent with 
a previous report which identified MDM-2 amplification as a rare occurrence in pediatric 
tumors (Waber et al., 1993). 
In addition, CCSK tumors did not exhibit MDR-1 overexpression by northern analysis. 
Lack of MDR-l expression in these tumors contrasts with that previously reported for an 
epithelial-predominant anaplastic Wilms' tumor that led to patient death (Re et al., 1997). 
These data also suggest that MDR-l overexpression is limited to cells with epithelial 
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differentiation, that CCSK tumors are not comprised of epithelial cells, and that this gene is 
not responsible for the potentially poor outcome in this tumor type. 
Since tumors with p53 mutations are not always detected USIng 
immunohistochemistry, we subjected both CMN and CCSK cell cultures to the DNA 
damaging chemotherapeutic drug cisplatin to test the ability of the p53 protein to transactivate 
its downstream effector genes p21, MDM-2 and Bax .This is a technique which has been used 
successfully in many cell types to evaluate p53 functional capabilities (O'Connor et al., 1997). 
Both of the CMN and CCSK cell lines exposed to cisplatin demonstrated p21 induction with 
varying kinetics over 8 hours of exposure. In contrast, anaplastic Wilms' tumor cells with p53 
mutations demonstrated a diminished to absent induction of p21. Flow cytometric cell cycle 
evaluation revealed G 1 cell cycle arrest in all CMN and CCSK cell cultures, but not in p53 
null W 4 anaplastic Wilms' tumor cells, demonstrating the ability of the p53 protein to mediate 
a signal transduction cascade, through p21 ,leading to cell growth arrest. Furthermore, the pro-
apoptotic Bax gene was induced in both CMN-1 and CCSK-2 cells over 20 hours. Bax mRNA 
levels declined, however, in CCSK-BG 1 cells. MDM-2 gene expression was also induced in 
CMN and CCSK cell lines with varying kinetics. p53 mRNA levels was not affected in any 
of the cisplatin treated cell lines indicating that p53 protein mobilization and not p53 mRNA 
induction is important in the cellular response to DNA damage. Previous reports have 
indicated that wild-type p53 protein induction occurs during the cellular response to DNA 
damage (Kastan et al., 1991). Therefore, CMN-l and CCSK-BG1 cells were exposed to 
cisplatin for intervals of two hours for a total of twenty hours. Both cell cultures exhibited 
protein stabilization over this time period consistent with the normal function ofp53. 
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Taken together, these data indicate that p53 mutations are not present in CCSK and 
CMN tumors, a finding that contrasts the p53 genotype in anaplastic Wilms' tumor cells. An 
explanation for the p53 nuclear reactivity in CMN cells is not known. However, the p53 
protein may be rendered more stable in cell culture conditions for these cell types. 
Alternatively, p53 may be stabilized by other p53 binding proteins such as 53BP2 (Gorina et 
aI., 1996). Previous studies have suggested that inactivation of p53 enhances the sensitivity 
of some cells to chemotherapeutic agents (Hawkins et al., 1996). For example, the p53 null 
W4 anaplastic Wilms' tumor cells, derived from a patient that died from disease, were more 
sensitive to cisplatin exposure than the CMN-l cell line which was derived from a benign 
tumor with a normal p53 gene. Therefore, this study also demonstrates the utility of evaluating 
the function ofp53 in pediatric renal tumor cells and has implications for the uses of DNA 
damaging agents as a chemotherapeutic treatment strategy in these tumors. 
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Figure 1. Immunocytochemical evaluation of p53 protein in cultured CCSK and CMN cells. 
Column A, Cells stained with mouse monoclonal antibody to p53 (clone DO-7) and 
rhoadamine-conjugated secondary goat anti-mouse antibody. Column B, corresponding phase 
micrograph to Column A. Column C, cells which received only secondary rhodamine-
conjugated goat anti-mouse antibody. Column D, corresponding phase micrographs to 
Column C. Rows indicate cell line evaluated. OVCAR (ovarian carcinoma) cells and 
anaplastic Wilms' tumor cells bear p53 mutations and act as controls for the p53 protein. 
Anaplastic W4 cells contain no immunochemically detectable p53 protein. 
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Figure 2. Northern analysis ofp21, p53, and GAPD in cisplatin treated CCSK and CMN cell 
cultures. Cell lines employed in experiment are indicated at top of blot. The different genes 
analyzed are noted at the left of each blot. Cisplatin exposure times are indicated above each 
lane in hours (0 hours = untreated cells). A, Induction ofp21 mRNA over 8 hours of cisplatin 
exposure. CMN-1, CMN-2, CCSK-2 and CCSK-BG 1 induced p21 mRNA in varying degrees. 
W 4 and W16 anaplastic Wilms' tumor cells bearing p53 mutations were included as negative 
controls. B, Evaluation ofp53 mRNA over 8 hours of cisplatin exposure. C, Hybridization 
with a GAPD cDNA fragment was included as a control for constitutive gene expression. 
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Figure 3. Northern analysis ofp53, p21, MDM-2, Bax, Bcl-xL and GAPD mRNA in CCSK 
and CMN cell cultures exposed to cisplatin. Cells employed in experiments are indicated 
above each blot. Genes analyzed are noted at the left of each blot. Cisplatin exposure times 
are noted above each lane. A, Northern analysis of p53, p21, MDM-2, Bax, and GAPD. 
Hybridization with a GAPD cDNA probe was included to ensure for equal lane loading in 
both A and B. W4 cells are included as a negative control for p53. C, Northern analysis of 





















Figure 4. Line Graph illustrating p21 waf-l mRNA quantification over twenty hours of 
exposure to cisplatin in CMN-l, CCSK-2, and CCSK-BGI cell cultures. A key to the right 
of the graph identifies the cell types used in the experiment. mRNA quantification was 
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Figure 5. Line graph illustrating p53 mRNA quantification over twenty hours of exposure to 
cisplatin in CMN-l, CCSK-2, and CCSK-BGI cell cultures. A key to the right of the graph 
identifies the cell types used in the experiment. mRNA quantification was performed using 
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Figure 6. Line graph illustrating MDM-2 mRNA quantification over twenty hours of 
exposure to cisplatin in CMN-1, CCSK-2, and CCSK-BG 1 cell cultures. A key to the right 
of the graph identifies the c~ll lines used in the experiment. mRNA quantification was 
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Figure 7. Line graph illustrating quantification ofBax and Bcl-X mRNA over twenty hours 
of exposure to cisplatin. A, Bax and Bcl-X mRNA quantification in CMN-I cells. B, Bax and 
Bcl-X quantification in CCSK~2 cells. Quantification was performed using Adobe Photoshop 
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Figure 8. Western blot analysis ofp53 and p21 protein in CMN-I and CCSK-BGI cells after 
20 hours of exposure to cisplatin. Exposure time is noted above each lane and cells used are 
indicated at the left of each blot. A, Western analysis ofp53 using the mouse monoclonal p53 
antibody (clone DO-7) showing p53 accumulation over 20 hours in both CMN-I and CCSK-
BG 1. B, p53 negative and positive controls. p53 mutant W4 cell extracts lack demonstrable 
p53 protein. p53 mutant WI6 cell line, in contrast, shows abundant p53 protein. C, Western 
analysis of p2I using a mouse monoclonal antibody in cisplatin exposed CMN -1 and CCSK-
BO 1 cells. p21 protein levels increased over 10 hours in CMN-l cells. In contrast, p21 protein 
levels rose between 2 and 6 hours in CCSK-BGI cells before declining at 8 hours. Equal 
amounts of protein were loaded into each lane. 
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Figure 9. Comparative Quantificationofp53 mRNA and protein in CMN-l and CCSK-BGI 
cell cultures. A, Quantification of p53 mRNA and protein over twenty hours of cisplatin 
exposure in CMN -1 cells. B, Quantification of p53 mRNA and protein over twenty hours of 
cisplatin exposure in CCSK -BG 1 cells. Quantification was performed using Adobe Photoshop 
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Figure 10. Flow cytometric cell cycle analysis of CMN -1 cells exposed to cisplatin over four 
hours. Relative DNA content and cell number represent the x- and y- axes, respectively. 
Percentage of cells in each phCl:se of the cell cycle are noted at the right of each histogram. A, 
Control, CMN-l cells receiving no cisplatin. B, CMN-l cells treated for two hours with 
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Figure 11. Flow cytometric cell cycle analysis ofCMN-2 cells exposed to cisplatin over four 
hours. Relative DNA content and cell number represent the x- and y- axes, respectively. 
Percentage of cells in each phase of the cell cycle are noted at the right of each histogram. A, 
Control, CMN-2 cells receiving no cisplatin. B, CMN-2 cells treated for two hours with 
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Figure 12. Flow cytometric cell cycle analysis of the p53 null, anaplastic Wilms' tumor W4 
cells exposed to cisplatin over four hours. Relative DNA content and cell number represent 
the x- and y- axes, respectively. Percentage of cells in each phase of the cell cycle are noted 
at the right of each histogram. A, Control, W4 cells receiving no cisplatin. B, W4 cells treated 
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Figure 13. Northern analysis ofp53, p21, MDM-2, MDR-1, and GAPD mRNA in CCSK 
primary tumor specimens. Tumor sample identity is noted above each lane. Genes evaluated 
are noted at the left of each blot.An ethidium bromide stained gel is included to document 
RNA integrity. KB-V 1 is a epidermoid carcinoma cell line known to contain amplified copies 
of the multi drug resistance gene, MDR-l. SJSA-l is a pluripotential sarcoma cell line with 
documented MDM-2 amplification. The presence ofp53 and p21 mRNA is noted in all CCSK 
examples with no evidence of gene rearrangement. CC-50013 (lane 3) contains a degraded 
RNA sample and is non-informative. There is no evidence of MDM-2 or MDR-l 
amplification or overexpression in any CCSK sample evaluated. Hybridization with a eDNA 















Figure14. Northern analysis ofpS3, p21, MDM-2 and GAPD in cellular (ce) and classical (cl) 
CMN primary tumor specimens. Tumor specimen identity is noted above each lane. Genes 
evaluated are listed to the left of each blot. An ethidium bromide gel is included at the bottom 
to document the integrity of each RNA sample. SJSA-l mRNA was derived from a 
pluripotential sarcoma with documented MDM-2 amplification. Both cellular and classical 
CMN contain pS3 and p21 mRNA with no evidence of gene rearrangement. There is no 
evidence ofMDM-2 amplification or overexpression in CMN primary tumors. Hybridization 










Table lA. Immunohistochemical Results on Frozen CCSK Primary Tumor Specimens 
Stain ed with p53 monoclonal antibody (DO-Tl 
Tumor Specimen Tumor Stage p53 
Case ID Immunoreactivity 
CC-209 Stage I -
CC-236 Stage II -
CC-462 Stage III -
CC-50057 Stage unknown -
CC-50113 Stage II -
ceCMN-357 Stage I -
c1CMN-458 Stage I -
c1CMN-482 Stage II -
ceCMN50044 Stage I -
ceCMN50524 Stage I -
esophageal squamous cell Stage unknown +++ 
carcinoma 
Table lB. Summary ofp53 Immunohistochemical and Gene Structure Data for CCSK 
and CMN C II C It P fft E b dd d P · T d X ft T·ssue e u ures, ara In m e e rlmary umor, an enogra 1 
Cell Culture p53 p53 p53 gene structure 
immunochemistry im m unochemistry 
cells paraffin 
CCSK-I +/- - NID 
CCSK-2 - - wild-type 
CCSK-3 - - NID 
CCSK-BG1 - - N/D 
CMN-I ++ - wild-type 
CMN-2 ++ +/- wild-type 
W 4 anaplastic - - point mutant 
W16 anaplastic ++++ ++++ point mutant 
Table II. Flow Cytometric Cell Cycle Analysis of Cisplatin Treated CMN and 
Anaplastic Wilms' Tumor Cells (Gl = Gl pbase ortbe cell cycle) 
p53 % cells in % cells in % cells in 
Cell Line 
p53 
Gl Gl Gl 1m m unoreactivity gene 
status untreated 2 hours 4 hours 
CMN-l positive wild-type 59.7 64.5 72.0 
CMN-2 positive wild-type 55.4 84.8 85.3 
W 4(anaplastic) negative mutant 24.4 25.8 26.0 
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Chapter 5 
Steady State and Retinoic Acid Induced Gene Expression Analysis of Clear Cell 
Sarcoma of the Kidney and Congenital Mesoblastic Nephroma: A Model 
For Tumor Histogenesis 
I. Introduction 
Pediatric renal tumors represent one of the most common abdominal tumors affecting 
young children and have long been interpreted as aberrations of normal nephrogenesis 
(Gonzalez-Crussi, 1984). These neoplasms may be subclassified based upon their clinical 
behavior, their association with genetic syndromes, cytogenetic lesions, and distinctive 
histological characteristics (Murphy et al., 1994). By far the most common childhood renal 
tumor, Wilms' tumor, or nephroblastoma, is most readily recognized as a developmental 
anomaly. These tumors are often characterized by their classical, triphasic histology which 
includes disorganized, immature tubular elements, blastema, and stromal tissue, or different 
combinations of the three latter cell types, structures which are also evident in the developing 
fetal kidney. Because of the close parallel in the cellular architecture between Wilms' tumor 
and fetal kidney tissue, it has been suggested that tumorigenic events probably occur during 
key points in the development of the kidney (Re et al., 1994). In contrast to the relatively 
straightforward interpretation of Wilms ' tumor histogenesis, the origins of other renal tumors 
of childhood are more subtle. One example is clear cell sarcoma of the kidney (CCSK) which 
was first delineated from Wilms' tumor in several reports dating to the 1970s (Kidd, 1970~ 
Beckwith et al., 1978). CCSK, which accounts for approximately 5% of all renal tumors of 
children, has Wilms' tumor distinguishing clinicopathologic features including a delicate 
chromatin pattern creating empty-appearing nuclei, prominent hyalinization, and a propensity 
for the development of bone metastases, a characteristic which sharply contrasts the usual 
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favorable outcome of most Wilms' tumors (Murphy et al., 1994). Although the histogenetic 
origin of this tumor is unknown, some have suggested that it may arise from renal medullary 
interstitial, mesangial, endothelial, or blastemal cap cells (Beckwith et al., 1978; Haas et al., 
1984). Authors of these same reports also speculated that CCSK may represent the malignant 
counterpart of the relatively benign, congenital mesoblastic nephroma (CMN) (Beckwith et 
al., 1978). Compared to CCSK, CMN is a relatively benigntumor first described by Bolande 
which primarily affects neonates as the vast majority of cases are diagnosed in the first three 
months of life (Bolande et al., 1967; Wigger, 1969). Like CCSK, CMN accounts for 5% of 
all childhood renal malignancies and is the most common abdominal tumor of neonates. 
CMNs may be further subdivided into two categories based upon their histology and clinical 
behavior: the classical and the more common and potentially more aggressive cellular CMN 
(Murphy et al., 1994; Joshi et al., 1986). Like CCSK, the developmental origin of CMN is 
unresolved even though its histological appearance suggests that it is a neoplasm of 
fibroblasts or myofibroblasts (Parham, 1996). Hypotheses regarding the histogenesis of both 
CMN and CCSK are primarily based upon electron microscopic studies and 
immunohistochemistry (Haas et al., 1984; Kumar et al., 1986; Pettinato et al., 1989). To date, 
the gene expression profile of CMN and CCSK have not been completely evaluated in the 
context of the genetic basis of normal kidney development. 
The development of the metanephros, or functioning adult kidney, occurs via 
reciprocal inductive events between the metanephric mesenchyme and the ureteric bud 
(Saxen, 1987). As development proceeds, metanephric mesenchyme differentiates into most 
structures of the nephron including the glomerulus and tubules. The ureteric bud, instead, 
134 
forms elements of the renal collecting duct system and the Columns of Bertin. With the 
introduction of molecular biological techniques, a large and varied array of genes which 
control normal kidney development have been identified (Lechner et al., 1997). 
WT -1 is a well recognized example. WT -1 is a zinc finger tumor suppressor gene that 
is deleted or mutated in Wilms' tumors and responsible for proper formation of the 
urogenital system (Call et al., 1990; Kreidberg et al., 1993). WT -1 expression is induced in 
metanephric mesenchyme following ureteric bud induction an remains expressed at high 
levels throughout the comma-shaped and S-shape stages of nephron formation. In the adult, 
WT -1 is only expressed in glomerular podocytes. WT -1 expression is also highly expressed 
in many Wilms' tumors, particularly in areas of blastema and tubular differentiation 
suggesting that Wilms' tumors are derived from areas of induced, condensing renal 
mesenchymal tissue (Pritchard-Jones et al., 1991). Two previous reports demonstrated the 
absence ofWT-1 transcripts in two cases each ofCCSK and CMN (Yun, 1993; Tomlison 
et aI., 1992). 
The WT -1 transcription factor mediates the expression of several key genes involved 
in fetal tissue growth and pediatric neoplasia including IGF-2. IGF-2 is overexpressed in 
many pediatric tumor types (Reeve et al., 1985). Interference of IGF-2 binding with its 
cognate receptor, IGF-1R, by the use of a monoclonal antibody specific for the receptor 
inhibits the growth of Wilms' tumors in vitro and in vivo (Gansler et aI., 1989). The latter 
suggests the importance of an IGF-2 autocrine growth loop in Wilms' tumor cell 
proliferation. Detection of an IGF -2 binding protein, BP-2, has also been described in 
Wilms' tumor cells, although the modulatory role that this protein plays in Wilms' 
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tumorigenesis or its role in IGF-2 mediated autocrine growth is unresolved (Vincent et al., 
1994). In other cell systems, BP2 has been reported to both inhibit and potentiate cell growth 
depending upon the cell system employed (Jones et aI., 1995). 
Pax-2 and Pax-8 are both paired box class transcription factors that are expressed in 
two partially overlapping, asynchronous waves during nephrogenesis. Pax-2, like WT-1, is 
induced following ureteric bud induction and persists throughout the early stages of 
nephrogenesis (Dressler et al., 1990). In contrast, Pax-8 is expressed at a later stage, as it 
remains expressed in the S-shaped body (Poleev et al., 1992). Like WT -1, expression of Pax-
2 an Pax-8 is a marker of induced metanephric mesenchyme; cells of the stromal lineage, 
presumably cells not receiving inductive signals, do not express WT -1, Pax-2, or Pax-So The 
expression pattern of the normal kidney closely parallels findings in Wilms' tumor. WT-l, 
Pax-2, and Pax-S are expressed in both blastema and areas of tubular differentiation in 
Wilms tumors, but not in stromal areas, as assessed by in situ hybridization (Eccles et al., 
1995). 
WT-1, Pax-2, and Pax-8 are all markers for renal tubules and the non-vascular 
glomerulus of the developing nephron. Very few markers have been identified for the 
developing renal stroma, or interstitium (Ekblom et al., 1991). Tenascin, a mesenchymal 
extracellular matrix protein, is expressed in areas of dense mesenchymal tissue immediately 
surrounding differentiating epithelium, a pattern which is consistent with that this protein is 
critical for normal mesenchymal to epithelial transformations in several developing organs, 
including the kidney (Chiquet-Ehrismann et al., 1986). Tenascin expression was absent from 
the uninduced mesenchyme and cells undergoing epithelial differentiation in developing 
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mouse kidney (Aufderheide et al., 1987). The latter study also reported persistence of 
tenascin expression in the medullary renal interstitial areas with loss of expression in renal 
cortical areas after nephrogenesis ceased. Others have demonstrated that tenascin 
immunoreactivity is also detectable in the glomerular mesangium with increased amounts 
noted in glomerulopathies and interstitial nephritides (Koukoulis et al., 1991). Therefore, 
these data suggest that tenascin may provide one of the few known markers for a better 
understanding of pediatric renal tumor histogenesis, particularly those with hypothesized 
stromal origins. 
The newly described marker of renal stroma, the winged-helix transcription factor BF -2, will 
also aid in the evaluation of both normal stromal development and the formation of pediatric 
renal tumors (Hatini et al., 1996). 
The use of differentiation agents such as all-trans retinoic acid (atRA) has been useful 
in understanding the pathobiology and histogenesis of a variety of tumor types including 
neuroblastoma and promyelocytic leukemia (Wada et al., 1992; Brietman et al., 1980). AtRA 
induces differentiation in cells by binding to nuclear Retinoic Acid Receptors (RAR) which 
are capable of homo- and heterodimerization with retinoid X-receptors. Among the effects 
of atRA on gene expression, is its potent induction of several RAR isoforms including RAR-
a during differentiation (Leroy et al' J 1991) Subsequently, these receptors bind to retinoic 
acid response elements (RARE) in target genes (Leid et al., 1992). Among other genes, 
expression of cell cycle regulatory genes p53 and p21 are also affected upon atRA treatment 
(Dony et al., 1985; Liu et al., 1996).Because Vitamin A derivatives including atRA have 
previously described utility in inducing differentiation in metanephros organ culture (Vilar 
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et al., 1996) and in other pediatric tumors including neuroblastoma, this differentiation agent 
was chosen to test the hypothesis that CCSK, CMN, and Wilms' tumors are each derived 
from precursor cells at different renal developmental stages. 
In this report, we have evaluated the expression profile ofWT-l, Pax-2, Pax-8, IGF-
2, BP-2, and tenascin using northern analysis in a series of CCSK and CMN primary tumors 
as a means of beginning to understand the histogenesis of these neoplasms in relation to 
Wilms' tumor. Furthermore, we have treated CCSK and CMN cell cultures with all-trans 
retinoic acid, evaluated changes in gene expression, and correlated these changes with 
morphological alterations assessed by transmission and electron microscopy. 
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II. Results 
1. Expression of Genes Involved in Normal Nephrogenesis in CCSK and CMN Primary 
Tumors 
A series ofCCSK (Figure 1) and CMN (Figure 2) primary tumors was examined for 
tenascin, WT-I, Pax-2, Pax-8, IGF-2, and BP-2 gene expression using northern analysis. 
Tenascin was expressed at low levels in 3/7 CCSK tumors. In contrast, tenascin mRNA was 
expressed at high levels in both cellular and classical CMN tumors. Tenascin expression was 
undetectable in an epithelial anaplastic Wilms' tumor (WI7) (Figure 2) and in the KB-VI 
epidermoid carcinoma cell line. Tenascin was expressed in a triphasic classical Wilms' 
tumor WI 1 (Figure 1). SJSA-I pluripotential sarcoma cells were included as an independent 
comparison in both panels and expressed low levels of tenascin mRNA (Figure 1&2). 
Expression ofWT -1 was absent in 100% of all CCSK primary tumors examined. In contrast, 
WT-I mRNA was detectable in 3/6 CMN tumors (1 classical and 2 cellular tumors). Both 
WI 1 and WI7 tumors expressed WT-I message. Pax-2 was variably expressed in 3/7 of 
CCSK and 1/3 ofCMN tumors examined. Both Wilms' tumors WI 1 and WI7 were included 
as positive controls for Pax-2 expression. Pax-8 mRNA was detected in one CCSK and two 
CMN tumors. IGF-2 and BP-2 were highly expressed in CCSK, CMN, and WT examined 
with rare exception. Hybridization with a GAPD cDNA probe was included as an indicator 
of constitutive gene expression. 
2. Phase Contrast Microscopy of atRA Treated CCSK and CMN Tumor Cells 
To attempt to understand the cellular origin for these rare renal neoplasms of 
childhood, cultured tumor cells were treated with the morphogen atRA for three days in a 
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dark incubator. Figure 3 illustrates the light microscopic characteristics of CCSK-2 and 
CCSK-BGI tumor cell cultures treated with 1 ~M atRA. Both untreated cell cultures 
demonstrated round to spindle shaped morphology. atRA treated cell cultures exhibited focal 
areas of close cellular clumping, in some instances forming mounds (Figure 3D). CCSK-2 
cultures also formed clusters of closely juxtaposed cells. Untreated CCSK-2 and CCSK-BG 1 
cell cultures were also noted to contain foci of closely opposed cells upon re-examination, 
however, indicating that the light microscopic features of these cells were not due to atRA 
exposure alone. 
Concurrent experiments treated SK -N -SH neuroblastoma cells and both CMN -1 and 
CMN-2 cells with 1 f..lM atRA (Figure 4). SK-N-SH cells exhibited the formation of 
interlacing neurite structures after 72 hours of atRA treatment indicating that neuroblastoma 
cells were induced to differentiate. In contrast, there was no light microscopic indication of 
cellular differentiation in either of the CMN cell cultures examined. Both cell cultures 
maintained a rounded spindle shaped morphology during the experiment. CMN-2 cells 
continued to grow in the presence of atRA as indicated by their increased cellular confluency. 
3. TEM and SEM Analysis of atRA Treated CCSK and CMN Cell Cultures 
The same atRA treated cell cultures ofCCSK-2 and CMN-I photographed using 
phase contrast microscopy were fixed for TEM and SEM analysis. Untreated CCSK-2 cells 
demonstrated cells growing in multipile layers by TEM (Figure SA) whereas those cells 
exposed to atRA for three days exhibited marked cellular interdigitation (Figure 5B).There 
was no apparent signs of intracytoplasmic organellar composition or development of 
intracellular filaments in treated versus untreated tumor cells. Furthermore, indications of 
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epithelial differentiation including the development of cell polarity was not found To better 
visualize the three dimensional affects of atRA on morphology, CCSK-2 tumor cells were 
examined using SEM. Whereas the untreated cells demonstrated cells with a dome-shaped 
morphology intermixed with flatter cells, atRA exposed cells were tightly opposed and 
flattened (Figure 5 C&D). 
CMN-l cells treated with atRA exhibited marked cellular changes by TEM and SEM 
analysis that were not apparent using phase microscopy alone (Figure 6). CMN-l cells that 
were not treated with atRA grew in sheets of cells that were not closely juxtaposed. Upon 
three days exposure to atRA, CMN-l cells became closely interdigitated and flattened 
leaving little intercellular space (Figure 6 B&D). As in CCSK-2 cells, there was no evidence 
of intracellular organellar change or development of intermediate filaments in CMN -1 cells. 
4. atRA Induced Gene Expression Alterations in CCSK and CMN Cells 
Total cellular RNA was extracted from CMN-l, CMN-2, CCSK-2, CCSK-BGl, and 
SK-N-SH neuroblastoma atRA treated cell lines were evaluated for alterations in mRNA 
expression for genes that are important for normal nephrogenesis using northern analysis 
(Figures 7-10). atRA exposed CCSK -2, but not CCSK -BG 1 cells exhibited induction of both 
tenascin and Pax-2 mRNA over a 48 hour time period. W17 and W16 anaplastic Wilms' 
tumor cells were included as a positive control for Pax-2 mRNA. IGF-2 mRNA levels 
initially increased in SK-N-SH neuroblastoma cells before declining at 72 hours. Neither 
CCSK-2 nor CCSK-BG 1 cells revealed IGF-2 mRNA differences over 48 and 72 hours of 
atRA exposure, respectively. RAR-a gene expression was induced in SK-N-SH 
neuroblastoma cells over 48 hours before declining at 72 hours. CCSK-2 cells demonstrated 
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no significant RAR-a induction over 48 hours. In contrast, CCSK-BG 1 cells revealed 
induction of the 3.5 kb RAR-a transcript over 72 hours with a concomitant decrease in a 
transcript migrating at 2.3 kb. There was no apparent change in p53 gene expression in any 
of the atRA treated cell cultures. Furthermore, there was no significant changes in p21 
expression in either CCSK-2 or CCSK-BG 1 cells, but a significant increase was noted in SK-
N-SH cells at 48 hours of atRA exposure. 
CMN-l, but not CMN-2 cells treated with atRA exhibited several gene expression 
alterations over 72 hours. In contrast to CCSK-2 cells, tenascin mRNA decreased in CMN-l 
cells with a concurrent induction ofPax-2 mRNA (Figures 9-10). IGF-2 and BP-2 mRNA 
levels remained stable in CMN-l cells through 48 hours before declining at 72 hours. RAR-a 
mRNA was induced in the first 48 hours in CMN-l cells before declining at 72 hours. 
Similar to the findings in CCSK cell cultures, both CMN cultures did not reveal any changes 
in p53 gene expression. p21 message, in contrast, was induced in SK-N-SH and declined at 
72 hours in CMN-l cells. Hybridization of RNA to a GAPD cDNA fragment was included 
as a control for constitutive gene expression. A model for the histogenetic origin of Wilms' 
tumor, CMN, and CCSK is presented in Table 11. This model is based on the steady-state 
and atRA induced gene expression profile of genes expressed during normal nephrogenesis. 
The hypothesized origins for these tumors are noted. 
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III. Discussion 
Current understanding of the histogenesis of pediatric renal tumors has been largely 
based upon light and electron microscopy and immunohistochemical studies (Haas et al., 
1984; Kumar et al., 1986; Pettinato et al., 1989). These reports have supported the distinction 
ofCCSK and CMN from Wilms' tumors and other childhood renal tumors. However, studies 
have not evaluated a sufficient number of cases to be meaningful due to the relative rarity of 
both neoplasms. Furthermore, the study of the cellular origin of these tumors has been 
hindered by the lack of an experimental model to test current CCSK and CMN histogenetic 
hypotheses. In the present study, we were able to evaluate a large series ofCCSK and CMN 
primary tumors for mRNA expression of genes controlling the normal nephrogenic program, 
such as WT-l Pax-2, and tenascin, in an effort to build a working model of the 
developmental origin of these neoplasms. Furthermore, both tumors were evaluated for 
morphological and gene expression alterations after treatment with the morphogen atRA in 
an in vitro differentiation assay. 
Previous molecular biological analysis of CCSK and CMN has been limited. Two 
independent studies reported that CCSK and CMN expressed the fetal mitogen IGF-2 and 
not the Wilms' tumor suppressor gene, WT-l (Yun, 1993; Tomlison et al., 1992). In the 
present study, WT -1 was not expressed in 7 CCSK primary tumors examined, although WT -
1 message was detected in three CMN tumors. In addition, WT -1 expression was previously 
detected in two CMN nude mouse xenografts. The latter represents the first reported 
expression ofWT-1 in this tumor type. Unlike WT-l, IGF-2 and the IGF-2 binding protein 
BP-2 were highly expressed in both CCSK and CMN supporting an embryological origin of 
143 
these tumors. Further analysis ofCCSK and CMN primary tumors revealed Pax-2 expression 
in selected tumor specimens. The latter contrasts with previous reports of one CCSK and one 
CMN which indicated no expression ofPax-2 or Pax-8 and other reports which demonstrated 
Pax-2 and Pax-8 expression in Wilms' tumors and in induced mesenchyme (Tagge et al., 
1994; Dressler et al., 1992; Poleev et al., 1992). The observation of both WT-l and Pax-2 
mRNA in some CMN and Pax-2 mRNA in selected CCSK has two alternative explanations. 
Firstly, the presence of Pax-2 mRNA may be explained by entrapped normal kidney 
glomeruli embedded within tumor tissue (glomerular podocytes express WT -1 postnatally). 
However, this explanation does not explain WT-l expression in cellular CMN xenografts 
analyzed previously since normal kidney tissue does not grow in nude mice. Alternatively, 
this data may indicate that CMN tumors are derived from mesenchymal cells in close 
juxtaposition with the condensing mesenchyme that receive inductive signals from the 
ureteric bud. Pax-2 expression in CCSK may be further indicative of the pluripotential nature 
ofCCSK cells (i.e. their ability to differentiate into cells oftubulogenic potential). Previous 
histological analysis of the three Pax-2 mRNA positive CCSK did not demonstrate evidence 
of epithelial differentiation, however. 
To clarify these results, CCSK and CMN were analyzed for tenascin mRNA 
expression, a marker of cells surrounding the condensing renal mesenchyme and interstitial 
cells (Ekblom et al., 1991; Aufderheide et aI., 1987; Truong et al., 1996). Tenascin 
expression was extremely high in all CMN tumors examined and contrasted with the variable 
and low tenascin mRNA content of CCSK. These data provides molecular evidence for the 
origin of CMN in the uninduced renal mesenchymal tissue that is destined to become the 
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interstitium of the kidney. Expression of tenascin in some CCSK further suggests the 
possibility of its differentiation along multipile differentiation pathways including the 
stromal lineage. The absence of WT -1, Pax-2, and tenascin expression in the majority of 
CCSK cases also supports the notion that this tumor arises in primitive, uncondensed renal 
mesenchyme. 
atRA is a well characterized inducer of neural cell differentiation in neuroblastoma 
cells (Robson et al., 1985) Due to this previously described utility of atRA, CCSK and CMN 
cell cultures were treated with the differentiation agent atRA to evaluate morphological and 
gene expression alteration.SK-N-SH neuroblastoma cells exhibited the characteristic 
formation of neurites by light microscopy in atRA exposed cells. However, phase 
microscopic analysis ofCCSK and CMN failed to demonstrate specific changes in cultures 
that received retinoic acid similar to previous reports of an atRA treated Wilms' tumor 
(Vincent et al., 1996). Both treated and untreated CCSK cultures, however, exhibited focal 
areas of close cellular opposition and cell clumping interspersed with flat stromal cells 
consistent with multipotential differentiation ofCCSK. CMN cells, in contrast, did not reveal 
any light microscopic evidence of epithelial differentiation. However, TEM and SEM 
analysis of both cell types treated with retinoic acid demonstrated marked changes in cellular 
arrangement without any effect on intracytoplasmic ultrastructural features. Both CCSK and 
CMN cultures exhibited marked cellular flattening and close cell juxtaposition in samples 
treated for three days with atRA. The latter cultures provided no evidence of epithelial 
differentiation in either tumor type as cell polarity, tight junctions, and rounded morphology 
were not identified. These results, then, are consistent with fibroblastic or smooth muscle 
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differentiation of CMN and CCSK. Previous studies in this laboratory identified smooth 
muscle actin positivity in both the CCSK-2 and CMN-l cultures used in this experiment. 
Future studies will include evaluating atRA induced changes in intermediate filament 
composition in these cells in order to further characterize the effects of this differentiation 
agent. 
Cells which were evaluated morphologically were also evaluated for changes in gene 
expression after exposure to atRA. Gene expression alterations varied within and between 
the cell types, but included induction oftenascin and Pax-2 in CCSK-2 cells. In contrast, 
CMN-l cells exhibited downregulation oftenascin mRNA with a concurrent induction of 
Pax-2 message. Tenascin induction in CCSK-2 cells provides further evidence for the origin 
of this tumor in the uninduced renal mesenchyme as atRA may have spurred these cells to 
differentiate into the interstitial lineage. The TEM and SEM and northern analysis data of 
CCSK-2 supports this hypothesis. In contrast to CCSK, CMN-l cells exhibited 
downregulation of tenascin in their differentiated phenotype. atRA has been previously 
reported to induce tenascin expression in neuroblastoma cells and is consistent with our 
findings in CCSK-2, but not CMN-l cells (Linnala et al., 1997). Pax-2 induction in CCSK-2 
and CMN -1 cells also suggests the origin of these tumors in the uninduced mesenchyme. In 
contrast to CCSK-2 and CMN-l, CCSK-BGI and CMN-2 cells do not exhibit gene 
expression alterations after atRA exposure. The latter further illustrates the heterogenous and 
pluripotential characteristics of these tumors. 
atRA has also been reported to modulate the expression of IGF-2 and BP-2 in 
neuroblastoma cell lines (Babajko et al., 1996). For that reason, these genes were evaluated 
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for changes in our CCSK and CMN cells. No changes in IGF -2 mRNA levels were evident 
in CCSK cells. However, CMN-l cells exhibited a downregulation of1GF-2 after 72 hours 
of treatment. In contrast, SK-N-SH cells included in this experiment induced IGF-2 mRNA 
at 48 hours supporting a previous report suggesting that IGF -2 induction is necessary for SK-
N-SH neuronal differentiation (Ueno et al., 1993). The lack oflGF -2 induction in CCSK and 
CMN cells of this study discounts the role of increased IGF-2 in the differentiation of these 
tumor cells. Downregulation of this gene in CMN-l at 72 hours suggests a resting cellular 
phenotype that does not require IGF-2 expression. Further, the concurrent downregulation 
ofBP-2 in CMN-1 cells lends support to the notion that BP-2 and IGF-2 function in tandem 
in these cells and that both are not needed, or are only required at low levels, to maintain the 
differentiated phenotype of these cells. This data does not discount the possible role of1GF-2 
in the process leading to differentiation, however. 
Finally, alterations in the expression of modulators of the cell cycle were also 
evaluated in these tumors. Previous reports have indicated that the cyclin-dependent kinase 
inhibitor, p21 is induced by retinoic acid exposure in hematopoietic and hepatoma cell lines 
and that this modulation of expression was mediated through RAR-a (Steinman et al., 1994; 
Liu et al., 1996). In our studies, p21 mRNA was not induced by atRA treatment in CCSK 
and CMN cells. However, p21 was induced in our control SK-N-SH cell line. In addition, 
the steady state level of p53 mRNA remained unchanged in CCSK and CMN cells. 
Uniquely,p21 mRNA declined at 72 hours in CMN-l cells, possibly indicative of a resting 
cellular phenotype. Therefore, upregulation of the p21 and p53 gene in CCSK and CMN cells 
does not appear to be a requirement for differentiation. Again, this data does not rule out the 
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possibility of post-transcriptional or post-translational mechanisms leading to increased p53 
or p21 stability as a means of atRA mediated differentiation of these tumor cells. 
In summary, atRA treatment ofCCSK and CMN cells caused dramatic morphological 
changes in both. These changes did not, however, demonstrate overt signs of epithelial 
differentiation in either tumor type. The distinct cellular flattening and close opposition of 
cells is more consistent with fibroblastic or smooth muscle cell differentiation. Gene 
expression alterations were variable in our tumor cell cultures, however, the changes noted 
may have implications for investigating the histogenesis and retinoic acid -mediated control 
of gene expression in these rare renal tumors of childhood in the future. Additionally, steady-
state examination of gene expression for Pax-2, WT -1, and tenascin strongly suggest that 
CMN cells arise from secondary mesenchyme destined to become the renal interstitium due 
their high expression oftenascin mRNA. In contrast, our data suggests that CCSK cells are 
derived from more primitive, pluripotent loose mesenchymal tissue. Some may argue that 
CCSK and CMN arise from cells that have already been induced and lost certain gene 
expression characteristics (such as WT -1 expression) linked to the condensing mesenchymal 
phenotype. Previous studies using retroviral markers dismiss this notion, however In studies 
of the embryological rat kidney, induced mesenchymal cells differentiated into proximal and 
distal tubular cells and glomerular epithelium, not renal interstitium (Herzlinger et al., 
1992).Future study of the expression of the BF -2 transcription factor, a newly described 
marker of immature renal stroma (Hatini et aI., 1996) would be helpful in further 
discriminating, or linking, these two stromal tumors. Because CCSK and CMN sometimes 
resemble other renal neoplasms, information gleaned from the further study of the 
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histogenesis of these tumor types has implications for the proper diagnosis, and therefore, 
treatment of these tumor types in the future. Further, the biological basis for the development 
of the normal renal interstitium remains unknown. Therefore, the use of these stromal tumor 
cultures may be useful in elucidating mechanisms of normal nephrogenesis as well. 
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Figure 1. A, Northern analysis of genes relevant to normal nephrogenesis including tenascin-
C, WT-l, Pax-2, Pax-S, IGF-2, BP-2, and GAPD in CCSK primary tumor tissue. Tumor 
specimens are noted above each lane of blots. A classical WT, Wll was included as a 
positive control for WT-l, Pax-2 and Pax-So Hybridization with a GAPD cDNA fragment 















Figure 2. A, Northern analysis of developmentally coordinated genes of nephrogenesis 
including tenascin-C, WT -1, Pax-2, Pax-8, IGF -2, BP-2, and GAPD in a series of cellular 
(ce) and classical (cl) CMN primary tumors. anaplastic Wilms' tumor W17 was included as 
a positive control for WT-l, Pax-2, and Pax-8 mRNA. Hybridization with a GAPD cDNA 
fragment was included to ensure for equal loading efficiency. B, Ethidium bromide stained 
gel of total cellular RNA. 
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Figure 3. Phase micrographs of untreated and atRA treated CCSK primary cell cultures. A, 
phase micrograph of untreated CCSK-2 cells. B, CCSK-2 cells treated for 3 days with 1 JlM 
atRA. C, Untreated CCSK-BG 1 cells. D, CCSK-BG 1 cells treated for 3 days with 1 JlM at 
RA. Cells treated with atRA did not demonstrate marked differences at the light microscopic 
level after 3 days of retinoic acid exposure. Although B and D demonstrate close cell 
opposition in both CCSK cultures after atRA exposure, these findings were also found 
focally in primary cell cultures not exposed to atRA. All micrographs at 200X. 
A. 
w/o retinoic acid B. wI retinoic acid 
c. D. 
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Figure 4. Phase micrographs of atRA and untreated CMN-l, CMN-2 and SK-N-SH 
neuroblastoma cells. A, untreated SK-N-SH neuroblastoma cells; B, SK-N-SH cells treated 
for 72 hours with 1 J.lM atRA; C, untreated cellular CMN-l cells; D, CMN-l cells treated 
for 72 hours with 1 J.lM atRA; E, untreated cellular CMN-2 cells; F, CMN-2 cells treated for 
72 hours with 1 J.lM atRA. A shows marked cellular clumping of SK-N-SH cells and 
contrasts greatly with the differentiated phenotype (evidenced by the formation ofneurites) 
in cells exposed to atRA for 72 hours (B). Arrows indicate neurite formation in B. There 
were no microscopically evident changes visualized in atRA treated CMN-l cells (C&D) or 
CMN-2 cells (E&F).All micrographs at 200X. 





Figure 5. TEM and SEM micrographs of untreated and atRA treated CCSK-2 primary cell 
cultures. A, TEM micrograph of untreated CCSK-2 cells growing in multipile layers with 
stromal morphology. B, TEM micrograph ofCCSK-2 cells exposed to 1 J,lM at RA for 72 
hours. C, SEM micrograph of untreated CCSK-2 cells. D, SEM micrograph ofCCSK-2 cells 
treated with 1 J.lM atRA for 72 hours. TEM and SEM analysis reveals marked cellular 
flattening in atRA treated cultures. TEM micrographs at 12,500X; SEM micrographs at 
500X. 
A. w/o retinoi·c acid B. wI retinoic acid 
c. D. 
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Figure 6. TEM and SEM micrographs of untreated and atRA treated cellular CMN-1 cells. 
A, TEM micrograph of untreated CMN-1 cells revealing multipile cell layers in culture. B, 
TEM micrograph CMN-1 cells treated for 72 hours in 1 f.lM atRA revealing cellular 
flattening and closer juxtaposition. C, SEM micrograph of untreated CMN-1 cells 
demonstrating cellular disarray and multipile cell layers. D, SEM micrograph ofCMN -1 cells 
exposed to 1 mM atRA for 72 hours showing interdigitation of tumor cells and cell 
flattening. TEM micrographs at 12,500X ;SEM micrographs at 2,OOOX. 
A. 
w/o retinoic acid B. wi retinoic acid 
c. D. 
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Figure 7. A, Modulation of gene expression in atRA treated CCSK and SK-N-SH 
neuroblastoma cell cultures. Cell lines evaluated are indicated at the top of the blots. 
Numbers over each lane correspond to hours of exposure to atRA. Genes evaluated are noted 
on the left of each blot. Three anaplastic Wilms' tumors W17, W 4, and W16 were included 
as controls for Pax-2, p53, and p21. Hybridization with a GAPD cDNA probe was included 
as a indication of constitutive gene expression. B, ethidium bromide stained agarose gel of 

























Figure 8. Line graph demonstrating quantification ofPax-2, tenascin, p21, p53, and IGF-2 
mRNA in CCSK-2 and SK-N-SH neuroblastoma cell cultures treated with atRA. Lines 
representing gene expression are identified in a key to the right of the graph. A, Alterations 
of gene expression in CCSK-2 cells exposed to atRA for a 48 hour period. B, Alterations of 
gene expression in SK-N-SH neuroblastoma cells exposed to atRA over a 72 hour period. 
Quantification was performed using Adobe Photoshop Version 4.0 software. 
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Figure 9. A, Modulation of gene expression in atRA treated cellular CMN and SK-N-SH 
neuroblastoma cell cultures. Cell lines evaluated are indicated at the top of the blots. 
Numbers over each lane correspond to hours of atRA exposure. Genes which were evaluated 
for RNA expression are noted at the left of each blot. Three anaplastic Wilms tumors, W17, 
W4, and W16 were included as controls for Pax-2, p53, and p21. Hybridization with a 
GAPD cDNA fragment was included to ensure equal loading of the gel. B, ethidiwn bromide 

















Figure 10. Line graph demonstrating quantification ofPax-2, tenascin, p21, p53, IGF-2,and 
IGF-BP2 mRNA in CMN-1 and SK-N-SH neuroblastoma cell cultures treated with atRA. 
Lines representing gene expression are identified in a key to the right of the graph. A, 
Alterations of gene expression in CMN-1 cells exposed to atRA for a 72 hour period. B, 
Alterations of gene expression in SK-N-SH neuroblastoma cells exposed to atRA over a 72 
hour period. Quantification was performed using Adobe Photoshop Version 4.0 software. 
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Figure 11. Model of CCSK and CMN histogenesis during normal fetal kidney development. 
A, the uninduced renal mesenchymal tissue which does not express the WT -1, Pax-2, Pax-8, 
or tenascin genes. A tumorigenic event in these cells may lead to CCSK. B, Secondary 
Mesenchyme destined to differentiate into elements of the renal interstitium. Cellular and 
classical CMN may derive be derived from this tenascin expressing tissue. C, Condensed, 
or induced renal mesenchyme which expressed WT -1, Pax-2, and Pax-8 during the inductive 



















Summary and Conclusions 
The study of CCSK and CMN in the past has been difficult due to the rarity of these 
tumor types and the inability of one research group to attain a sufficient number of these 
tumors types for evaluation. This study reports, for the first time, the development of both an 
in vivo and in vitro model system by which to study these rare renal neoplasms of childhood 
in relation to Wilms' tumor and other pediatric malignancies. 
Both cell cultures and nude mouse heterotransplants demonstrate similarities with their 
respective primary tumor specimens when evaluated histologically!, ultrastructurally!' and 
molecularly. Immunohistochemical characterization of cell lines has novelly demonstrated 
SMA immunoreactivity in both CCSK cultures. The latter findings may suggest that CCSK is 
a tumor derived from smooth muscle or a tumor which is derived from glomerular mesangial 
cells of the kidney, as both are positive for the smooth muscle actin protein. Interestingly, SMA 
immunoreactivity was limited to arterial smooth muscle cells in Carnoy's fixed paraffin 
embedded CCSK primary tumor tissue. The latter suggests that the cell culture environment 
(i.e. a collagen matrix) may have a differentiating effect upon CCSK cells. An origin in one 
of these cell types is consistent with northern analysis data which has shown negativity for 
markers of early induced mesenchyme such as WT -1, Pax-2 and Pax-8. Further, CCSK tumor 
specimens demonstrated low levels oftenascin mRNA, a gene expressed only in the immature 
stroma and renal interstitium of the kidney. In contrast, immunochemical findings in CMN are 
consistent with their primitive mesenchymal origins and supportive of a histogenetic origin in 
the early stromagenic cells. A panel of CMN primary tumor specimens expressed high levels 
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oftenascin mRNA. The latter may be indicative a early stromagenic origin for this tumor type 
and supports previous light and electron microscopic studies implicating fibroblasts and 
myofibroblasts as the cell of origin for this tumor type. Like CCSK, CMN failed to 
demonstrate mRNA for markers of induced mesenchyme and early epithelial progenitor cells 
such as WT -1. 
Due to the their similarity in histologic appearance, it has long been speculated that 
CCSK and CMN may be linked in a tumor progression pathway (i.e. CMN may represent the 
benign counterpart of the potentially aggressive CCSK). A similar association between 
classical and anaplastic Wilms' tumors has suggested that the tumor suppressor protein, p53, 
may be involved in progression. Karyotypic and immunohistochemical analysis of p53 has 
suggested that this tumor suppressor may be involved in the pathogenesis of CCSK. 
Immunohistochemical analysis of a large panel of CCSK and CMN in this study, however, 
does not indicate that p53 is involved in CCSK pathogenesis. In fact, p53 immunoreactivity 
was only demonstrated in cell cultures of the benign CMN and not in the CCSK cells, 
contradictory to the supposed role of p53 in tumor progression. Further analysis of CCSK and 
CMN cells using a DNA damage response assay confirms our previous immunohistochemical 
findings in primary tumors that p53 is functional in these two tumor types. Functioning p53 
molecules in CCSK suggests the possibility of another mechanism for the clinical 
aggressiveness of this tumor type. Other mechanisms which might contribute to p53 
dysfunction were also examined in this study. Pathologic overexpression of the p53 binding 
protein, MDM-2, a protein which renders p53 inactive, was not present in a large panel of 
CCSK, CMN, and Wilms' tumors. Even though the increased p53 protein stability in CMN 
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cells remains unresolved, there may be several alternative explanations. For example, the cell 
culture environment may cause an upregulation of p53 mRNA translation as a protective effect, 
or p53 protein is rendered more stable due to a post-translational mechanism. Alternatively, 
p53 protein stability might be associated with the presence of an as yet unidentified p53 
binding protein in these cells. These two model cell lines may be useful in identifying such a 
protein or proteins. 
The functional analysis of p53 may also have prognostic utility as cells with mutations 
are sometimes more sensitive to chemotherapeutic agents which render DNA damage such as 
cisplatin and doxorubicin. Preliminary results in this laboratory have suggested that the 
multi drug resistant anaplastic Wilms' tumor cell line W4, containing a p53 null genotype, is 
particularly sensitive to cisplatin. The latter may be explained by the tumor cell's inability to 
arrest and repair DNA damage. Thus, when enough damage has accumulated, cells will die. 
The use of platinum agents (which are non-MDR drugs) in anaplastic tumors that are multidrug 
resistant and p53 null may be clinically useful. 
CCSK and CMN undoubtedly represent aberrations of normal kidney development as 
children aged newborn through four years of age are most likely to be afflicted by this 
neoplasm. The study of the in vivo and in vitro model of these tumor types has potential 
usefulness in understanding normal nephrogenesis. The cellular and molecular mechanisms 
for the development of the renal stromal interstitium remains relatively unexplored. The latter 
contrasts greatly with the amount of information concerning the development of the renal 
tubular cell system. Renal interstitial cells and renal mesangial cells only comprise a small 
component of the normal adult kidney and their embryology remains unexplained. However, 
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both of cell types are associated with significant pathologies. For example, pathological 
deposition of extracellular matrix material is associated with glomerulosclerosis in disease 
states such as diabetes mellitus and lupus erythematosus. Interestingly, immunohistochemical 
analysis of CCSK cells in this study demonstrated smooth muscle actin positivity, a protein 
which is expressed in normal human mesangial cells. Further, one of the hallmark histologic 
features of CCSK is the deposition of collagenous extracellular matrix. Therefore, it follows 
that CCSK may be a pathological proliferation of early, precursor mesangial cells. If so, CCSK 
cell lines and tumor heterotransplants may be important models for better understanding the 
mechanisms of abnormal extracellular matrix deposition in diabetic and autoimmune 
compromised human mesangial cells. Therefore, in vitro and in vivo models of CCSK will be 
useful in understanding the mechanisms of neoplasia in this tumor type as well as a potentially 
useful model in the study of renal embryology, diabetic glomeruloscelerosis, 
membranoproliferative glomerulonephritis, lupus nephritis, IgA nephropathy, as well as others. 
Several additional experiments would continue to address the histogenesis of CCSK 
and CMN and mechanisms of normal kidney development. Using our developed cell lines, cell 
co-culture experiments including CMN cells and renal mesenchyme may provide evidence for 
the origin of this tumor. That is, if CMN is truly of secondary mesenchymal origin, then 
cultured tumor cells may express a soluble factor which orchestrates the development of renal 
vesicles, and eventually normal tubular epithelium. Secondly, both CCSK and CMN cells 
would be useful in transfection experiments. Several genes have important roles in the 
mesenchymal to epithelial transformation of the kidney and include E-cadherin, ovumorulin, 
hepatocyte growth factor, WT-l, Pax-2, and wnt-4. CCSK and CMN should be examined for 
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their mRNA and protein expression of these genes. Furthermore, cellular transfection of these 
genes may provide important clues for the origins of both tumor types. For example, would 
Wilms' tumor-l transfection initiate epithelial differentiation ofCMN or CCSK tumor cells? 
Lastly, tumor cells or xenografts derived from these tumor types should be treated with other 
inducers of kidney development such as low concentrations of lithium. Or, more importantly, 
these cells should be exposed to a biological inducer such as developing bone tissue to evaluate 
morphological and molecular alterations. 
More recent findings in the genetic control of normal kidney development may also 
provide clues to the origins of pediatric renal tumors. For example, the BF-2 transcription 
factor is expressed in early stromal cells and is thought to mediate their development in a 
mouse model. A logical experiment would be to evaluate tumors which supposedly represent 
aberrations of stromal development for defects in this gene. In BF -2 knockout mice, stromal 
cells appear to develop normally, however, the kidney itself is smaller than normal, ducts have 
limited branching, and fewer mesenchymal aggregates to differentiate. CCSK, CMN, and 
Wilms' tumor, characterized by the apparent arrest of differentiation, may be a useful model 
for the study ofBF-2 abnormalities. And, more importantly, CMN and CCSK cell lines will 
hopefully provide tools for a more complete understanding of the molecular basis of normal 
kidney development. 
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